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Introduction
INTRODUCTION
Peripheral nerve blocks are gaining widespread popularity for
perioperative pain management because of their distinct advantages over
general and central neuraxial anesthesia. Pain relief with peripheral nerve
block (PNB) is devoid of side effects such as somnolence, nausea,
vomiting, hemodynamic instability and voiding difficulties inherent to
general and central neuraxial anesthesia.
Brachial plexus blocks (interscalene, supraclavicular and
axillary blocks) 1-10 provide a useful alternative to general anesthesia for
upper limb surgery. Each  of  these  routes  has  its  own  particular
advantages, disadvantages and complications. They achieve ideal
operating conditions by producing complete muscular relaxation,
maintaining stable intraoperative hemodynamic, and the associated
sympathetic block. The sympathetic block decreases postoperative pain,
vasospasm and edema. Supraclavicular perivascular brachial plexus block
is a very commonly practised technique in patients undergoing surgery on
forearm and hand. Supraclavicular block as opposed to infraclavicular
brachial plexus block generally offers denser and complete upper limb
anaesthesia. Nerve stimulators are now widely seen as useful aids in nerve
2blocks (11,12). Its use avoids paraesthesia, decreases the chance of nerve
injury and gives high success rate.
Introduction of long acting local anesthetic with better safety
profile as well as better equipment has further increased the usage of
peripheral nerve blocks. Bupivacaine hydrochloride, a long acting local
anaesthetic agent, has been used extensively for supraclavicular brachial
plexus block 13. Ropivacaine 14-26,  the  S- enantiomer of S-1-propyl-2,6-
pipecoloxylidide, is an amino-amide local anaesthetic with chemical
structure similar to that of bupivacaine. Ropivacaine is a potent blocker of
A delta and C fibres (pain fibres). It has been reported to be less toxic
than Bupivacaine.
In  contrast  to  Bupivacaine  which  is  a  racemic  mixture  of  R and S
enantiomers, Ropivacaine is the first local anesthetic that has developed
as a pure enantiomer. S enantiomer is considered less neurotoxic and
cardiotoxic 42 than the R enantiomer of local anesthetics, perhaps
reflecting different pharmacodynamics, pharmacokinetics and toxicities.
Studies18,23-26 have shown that Ropivacaine and Bupivacaine when given
in equal volumes was similar in terms of onset and duration of sensory
block and frequency of motor block.
3The addition of epinephrine does not prolong the duration of
Ropivacaine in subclavian perivascular brachial plexus27-28 or epidural
block. Low concentrations of Ropivacaine may produce clinically
significant vasoconstriction which is not further increased by the addition
of epinephrine.
This study attempts to compare the safety and efficacy of 0.5%
Ropivacaine without epinephrine and 0.5% Ropivacaine with epinephrine
and 0.5% Bupivacaine in patients receiving subclavian perivascular
brachial plexus block.
Aim of the
Study
4AIM OF THE STUDY
To study the efficacy and safety of 0.5% Ropivacaine without
epinephrine and 0.5% Ropivacaine with epinephrine and 0.5%
Bupivacaine in patients receiving subclavian perivascular brachial
plexus block.
History
5HISTORY
The first effort for the achievement of local or regional anesthesia
dates back to the middle ages, where Ambroise Pare described in 1564 in
France “that anesthesia was used to carry out operations at the
extremities”, with the help of the compression mechanism intended to
bring about analgesia, while in 1846 in Italy M.A. Severino brings about
local anesthesia by putting ice or snow on the surgical field29.
Nevertheless, the real regional anesthesia started upon discovery of the
holed metallic wire in 1854 by Wood, as well as the local anesthetic
properties of cocaine29.
Cocaine is contained in the leaves of a plant, the mahogany of
coca, which is grown in the South American countries 29,30.Cocaine was
isolated from the leaves of the of the coca’s mahogany for the first time in
1860, by A. Niemann in Germany. The substance was crystalline,
colourless, odourless and with a sour taste. In 1884 Karl Koller from
Vienna described at the conference of German ophthalmologists in
Haideberg the anesthetic qualities of a 2% cocaine solution after it was
instilled in the eye 31. In 1885 Halstead, on the one hand, gave a
description of the exclusion of the nerve through infiltration with cocaine,
and Corning from the United States, on the other hand, gave a description
of the episcleroid anesthesia, which most probably, though, corresponded
6to the paraverterbral exclusion. Thus, cocaine, managed to acquire the
prestige it deserved as a local anesthetic after a number of fatal
implications was recorded from the acid action of the solutions with a
high cocaine content that they were using at that time.
The revolution in the history of local anesthetics broke in 1904,
when Einhorn introduced novocaine (procaine), a local anesthetic with
fewer side effects than cocaine. Nevertheless, the duration of its action
has been short-lived, a fact which has limited its use for the most part to
operations with a short duration. This problem was solved by Braun, who
proposed the addition of adrenaline to the local anesthetic, for the purpose
of prolonging both the duration and the validity of the local anesthetic.
In 1943 Nils Loefgren composed lidocaine, which belongs to the
group of aminoalcylamides . Beyond any doubt, the lidocaine has been
the main substance and, at the same time, the base for all the later studies
of the local anesthetics that followed. The later researches led to the
discovery of new local anesthetics such as etidocaine, the prilocaine, and
the bupivacaine.
THE DEVELOPMENT OF THE MODERN LOCAL ANESTHETICS
Albright’s announcement on the quest of new local anesthetics
in 1979 with regard to the heart failures following the administration of
etidocaine and bupivacaine is believed to be significant 32. After this
7announcement, there followed a constructive discussion with regard to
the toxicity of the local anesthetics 33, 34. There followed experimental
studies, which confirmed the assumption of Albright that deaths were the
result of the high cardiotoxicity of the long-lasting local anesthetics 35-38.
During the search for new local anesthetics, the researchers utilized
the characteristic fabrication of the 3-dimensional molecular structure that
the bupivacaine can demonstrate 39. The meaning of “stereo-isomery” had
been introduced at the end of the 19th century by the Swede chemist von
Berzelius (1779 through 1848). Thus, the Bupivacaine (racemic mixture
with R- and S-form in the same percentage) helped produce ropivacaine
(net S-enantiomer).
Ropivacaine is produced through the halcyliosis of the S-
enantiomer of L-staphylitic-dibenzoic-acid-ester. Its chemical structure
has a great similarity with that of bupivacaine and of mepivacaine, while
its two-dimensional form has a few only differences from that of
bupivacaine. Ropivacaine does not differ as regards the physical and
chemical properties from racemic mixture. The only difference that it
presents as compared with bupivacaine is its lipophilia, which is
comparable with that of mepivacaine.
The significant progress that the introduction of this short-lived
local anesthetic in the clinical practice relies, on the one hand, upon the
8reduced toxicity on the cardiovascular and central nervous system and, on
the other hand, on its dose-dependent differential closeout (the qualities
of which we can utilize in the postoperative analgesia and the
administration of epidural anesthesia in the obstetrics) 40-43. The wide
acceptance of ropivacaine in the clinical practice was followed by the
preparation of a number of other substances by the group of amides, for
the purpose of introducing them into the clinical practice. Meanwhile, an
S-enantiomer of bupivacaine, the levobupivacaine, which, based on the
first clinical experiences, has proven the same profile of action, such as in
the racemic mixture which has been used so far in the various techniques
of the anesthesia area 44, 45. Levobupivacaine is governed by an equally
large lipophilia such as the bupivacaine and that for this reason it differs
to a great extent from the ropivacaine, mainly as to the power, the
kinetics on the receptor level and, quite possible, as to the cardiac
toxicity. Due to the high lipophilia which governs it, the power of the
levobupivacaine is higher that than of ropivacaine, while its kinetics at
the level of the receptor is quite probably comparable to that of
Bupivacaine.
Anatomy of
Brachial Plexus
9ANATOMY OF BRACHIAL PLEXUS 46-49
Knowledge of the formation of the brachial plexus and its
distribution is essential to the intelligent and effective use of the brachial
plexus blockade for the surgeries of the upper limb. Close familiarity with
the vascular, muscular and fascial relationship of the plexus throughout
the formation and distribution is equally essential to the mastery of
various techniques of Brachial plexus Blockade.
In its course from the intervertebral foramina to the arm, the fibre’s
that constitute the plexus are composed consecutively of roots, trunks,
divisions, cords and terminal branches, which are formed through a
complex process of combining, dividing, recombining and finally
redividing.
The brachial plexus is formed by the union of the anterior primary
rami of the fifth, sixth, seventh, eighth cervical nerves and the first
thoracic nerve, with variable contributions from the fourth cervical
(pre fixed) above and second thoracic nerve (post fixed) below. These
nerves unite to form trunks, which lie in the neck above the clavicle. Its
roots pass between the scalenus anterior and scalenus medius which is
enclosed by fascia accompanied by the subclavian artery and then
invaginates the scalene fascia to form a neurovascular bundle. This fascia
becomes the axillary sheath in the axilla.
ANATOMY OF BRACHIAL PLEXUS
SENSORY INNERVATIONS OR UPPER LIMB
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RELATION OF BRACHIAL PLEXUS:
Anterior relations:
The skin, superficial fascia, platysma, supraclavicular branches of
the superficial cervical plexus, deep fascia and external jugular vein. The
clavicle is in front of the lower part and scalenus anterior is in the front of
the upper part.
Posterior relations:
Scalenus medius and the long thoracic nerve of bell.
Inferior relations:
Related to the first rib.
Superior relations:
Lies first above and then lateral to the subclavian artery.
SYMPATHETIC CONTRIBUTION TO THE PLEXUS:
Close to the emergence, the fifth and sixth cervical nerves, each
receive a grey ramus from the middle cervical sympathetic ganglion. The
seventh and eighth cervical nerves each receive a grey ramus from the
inferior cervical ganglion.
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ROOTS:
Anterior primary rami of C5, C6, C7, C8 and T1 (occasionally C4
or T2)
TRUNKS:
? Upper trunk - Anterior rami C5 and C6
? Middle trunk – Anterior ramus of C7
? Lower trunk – Anterior rami of C8 and T1
DIVISIONS:
Behind the clavicle each trunk divides into anterior and posterior
divisions.
CORDS:
? Lateral cord – Anterior divisions of upper and middle trunks
(C5-C7)
? Medial cord – Anterior divisions of lower trunk (C8-T1)
? Posterior cord – Posterior divisions of all the three trunks (C5-T1)
BRANCHES:
From roots:
? Nerve to Serratus anterior (C5, C6, and C7)
? Muscular branches to longus cervices (C5, C6, C7, and C8)
? Nerve to Scalene (C5, C6, C7 and C8)
? Nerve to Rhomboids(C5)
? A twig to Phrenic nerve (C5)
12
From trunk:
? Nerve to subclavius (C5-C6)
? Suprascapular nerve (C5-C6)
From cords:
Lateral cord:
? Lateral root of median nerve (C5, C6 and C7)
? Lateral pectoral nerve (C5, C6 and C7)
? Musculocutaneous nerve (C5, C6 and C7)
Medial cord:
? Medial root of median nerve (C8, T1)
? Medial cutaneous nerve of arm (C8, T1)
? Medial cutaneous nerve of forearm (C8, T1)
? Medial pectoral nerve (C8, T1)
? Ulnar nerve (C8, T1)
Posterior cord:
? Radial nerve (C5- T1)
? Axillary nerve (C5-C8)
? Upper and lower subscapular nerve (C5, C6)
? Nerve to lattismus dorsi (C6, C7, C8)
Familarity with the perineural structures that surround and
accompany the brachial plexus as it leaves the vertebral column on its
course to the upper arm is as important as the knowledge of the formation
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and distribution of the neural plexus itself. Palpable muscular and
vascular landmarks allow accurate location of the plexus percutaneously.
An appreciation of the fascial relations is absolutely essential since this is
the basis for all the perivascular techniques.
After leaving the intervertebral foramina, the anterior primary rami
of the nerves destined to become the brachial plexus travel in the gutter
formed by the anterior and posterior tubercles of the corresponding
transverse processes of the cervical vertebra. After leaving the transverse
processes, the roots of the plexus descend in front of the middle scalene
muscle, which arises from the posterior tubercles of the transverse
processes of lower six cervical vertebra. The insertion of this muscle on
the first rib is separated from that of the anterior scalene muscle by the
inferior trunk of the brachial plexus. The anterior scalene muscle arises
from the anterior tubercles of the transverse processes of the third to sixth
cervical vertebrae and inserts on the scalene tubercle of the first rib, thus
separating the subclavian artery from the subclavian vein.
The fascia covering both the scalene muscle is derived from the
prevertebral fascia, which splits to invest these muscles and then fuses
again at their lateral margins to form an enclosed inter scalene space.
Therefore as the roots leave the transverse processes, they emerge
between the two walls of the fascia covering the anterior and middle
scalene muscles. In their descend towards the first rib to form the trunks
of the plexus the roots may be considered to be sandwiched between the
anterior and middle scalene muscle, the fascia of which serves as a sheath
SURFACE ANATOMY FOR SUPRACLAVICULAR BLOCK
SUPRACLAVICULAR BLOCK: PERIVASCULAR AND PLUMB BOB
APPROACHES
SUBCLAVIAN PERIVASCULAR BLOCK ANATOMY: BRACHIAL PLEXUS
VIEWED FROM ABOVE
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of the plexus. As the trunks approach the first rib they are arranged one
above the other vertically.
As the trunks of the plexus cross the first rib, they are joined by the
subclavian artery, which lies in a plane anterior to the trunks, so that the
inferior trunk lies behind the artery in the subclavian groove with the
middle and superior trunks above the level of the vessel. At this level the
artery and the trunks are moving laterally, across the ribs and invaginate
the scalene fascia to form the subclavian perivascular space, which is
continuous medially and superiorly with the interscalene space and
inferiorly and laterally with the axillary perivascular space.
The important concept is that there is a continuous fascial enclosed
perineural and perivascular space extending from the cervical transverse
processes to several centimeters beyond the axilla; this space has been
divided into a axillary perivascular space and interscalene space. The
existence of such a continuous perineural space renders brachial plexus
block simple. The space described may be entered at any level, and the
volume of the anesthetic injected at this level would determine the extent
of anesthesia. Thus, the technique to be used in any case should be
determined on the basis of the surgical site, the required level of
anesthesia, the physical status and habitus of the patient.
Brachial plexus can be blocked at the level of roots, trunks, cords,
peripheral branches. The block at each level has a distinct distribution of
anesthesia, advantages, disadvantages and complications.
Peripheral
Nerve
Stimulator
Technology
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PERIPHERAL NERVE STIMULATOR
TECHNOLOGY 11,12,50-56
The ability of a nerve stimulator to evoke a motor response
depends on the intensity, duration, and polarity of the stimulating current
used and the needle (stimulus)-nerve distance. To propagate a nerve
impulse, a threshold current must be applied to the nerve fibre. Peripheral
nerve stimulation is typically performed using a rectangular pulse of
current. When a square pulse of the current is used to stimulate a nerve,
the total charge delivered is the product of the current strength and the
duration of pulse.
RHEOBASE-is the minimal threshold current required to stimulate
a nerve with a long pulse width.
CHRONAXIE- is the duration of the stimulus required to stimulate
at twice the rheobase. Chronaxie is used to express the relative
excitabilities of different tissues. It is possible to stimulate A-? (motor)
fibres without stimulating A-? and C fibres that transmit pain. Moreover,
mixed nerves can be located by evoking a motor response without
causing patient discomfort. Stimulation intensity will be variable as
determined by coulomb’s law. A very high stimulus current is required to
stimulate the nerve when the needle tip is far away from the nerve. If the
distance is great, the strength of the stimulus required to stimulate the
PERIPHERAL NERVE LOCATOR
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nerve may produce significant pain and systemic effects. An EMR at a
stimulating current of <0.5mA is associated with high rates of success of
PNS assisted PNB.
Characteristics of an ideal PNS:
1. Constant current output-A particular current not the voltage
stimulates the nerve. Therefore, the current delivered by the
device should not vary with changes in the resistance of the
external circuits.
2. Digital display of the delivered current
3. Variable output control
4. Clearly identifiable polarity
5. Option for different pulses
6. A wide range of current output 0.1-5.0mA
7. Battery indicator
Peripheral nerve stimulator settings:
? MIXED NERVE(most PNB)
a. Current(dial) - 1mA
b. Current duration - 0.1ms
c. Frequency - 1-2Hz
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? SENSORY NERVE
(eg- Lateral femoral cutaneous and saphenous nerves)
a. Current (dial) - 2-5mA
b. Current duration - 1ms
c. Frequency - 1Hz
? DIABETIC NEUROPATHY(PNB)
a. Current(dial) - 2mA
b. Current duration - 0.3ms
c. Frequency - 1-2HZ
Pharmacology
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PHARMACOLOGY 20,43,57-59
LOCAL ANESTHETICS
Mechanism of action of local anesthetics:
Impulse blockade by local anesthetics may be summarized by
the following chronology
? Solutions of local anesthetic are deposited near the nerve. Removal
of free drug molecules away from this locus is a function of tissue
binding, removal by the circulation, and local hydrolysis of
aminoester anesthetics. The net result is penetration of the nerve
sheath by the remaining free drug molecules.
? Local anesthetic molecules then permeate the nerve’s axon
membranes and reside there and in the axoplasm. The speed and
extent of these processes depend on a particular drugs pKa and on
the lipophilicity of its base and cation species.
? Binding of local anesthetic to sites on voltage gated Na+ channels
prevent opening of the channels by inhibiting the conformational
changes that underlie channel activation. Local anesthetics bind in
the channel’s pore and also occlude the path of Na+ ions.
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? During onset of and recovery from local anesthesia, impulse
blockade is incomplete and partially blocked fibers are further
inhibited by repetitive stimulation, which produces an additional,
use- dependent binding to Na+ channels
? One local anesthetic binding site on the Na+ channel may be
sufficient to account for the drugs resting and use-dependent
actions. Access to this site may potentially involve multiple
pathways, but for clinical local anesthetic, the primary route is the
hydrophobic approach from within the axon membrane.
? The clinically observed rates of onset and recovery from blockade
are governed by the relatively slow diffusion of local anesthetic
molecules into and out of the whole nerve, not by their much faster
binding and dissociation from ion channels. A clinically effective
block  that  may  last for hours can be accomplished with local
anesthetic drugs that dissociate from Na + channels in a few
seconds.
BUPIVACAINE HYDROCHLORIDE
It is an amide local anesthetic synthesized by B.O. Af. Evenstam in
1957 of AB Bofor in Sweden. First came into clinical use in 1963 by
Widman & Teliuvo.
Chemistry:
An amino amide local anesthetic having aromatic moiety ( benzene
ring), which offers lipophilicity to one end of the molecule. It is linked by
an amide to a tertiary amine, which is hydrophilic on the other
molecule. IUPAC Name:
carboxamide
It displays stereoisomerism.
optically active enantiomers R and S. S
have slightly longer dura
compared to R-type.
Presentation:
As a clear solution of 0.25/05% bupivacaine hydrochloride. The
hyperbaric solution contains 8
Physico chemical properties
? Molecular Weight
? pKa(25 °C)
? Protein Binding
1-buty1-N-(2,6-dimethylpheny
Marked as a racemic mixture containi
-enantiomers have been noted to
tion of action and lower systemic toxicity when
-mg/ml of glucose.
:
: 288
: 8.1
: 95%
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end of the
l)piperidine-2-
ng
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? Lipid Solubility : 28
? Fraction  nonionized at pH 7.4 - 17%
pH7.2 - 11%
Pharmacokinetics:
Local anesthetics are weak bases with pK values somewhat above
physiologic pH. As a result < 50% of the local anesthetic exists in a lipid
soluble non ionized form at physiologic pH. Intrinsic vasodilator activity
of bupivacaine will also influence the potency and duration of action.
The absorption of local anesthetics is related to
? The site of injection ( Intercostals > Epidural> Brachial Plexus >
Subcutaneous)
? The dose: a linear relationship exists between the total dose and the
peak blood concentration achieved.
? The presence of vasoconstrictors which delay absorption.
? Pharmacologic characteristics of the drug.
Lipid solubility, tissue blood flow, age, cardiovascular status and
hepatic function will influence the absorption and the resultant plasma
concentration of the drug. Protein binding of the drug will influence the
distribution and elimination. Alpha1 acid glycoprotein is the most
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important protein binding site of Bupivacaine. Volume of distribution is
73 liters.
The possible pathways for metabolism of Bupivacaine include
aromatic hydroxylation, N-dealkylation, amide hydrolysis and
conjugation. Only the N-dealkylated metabolite N-desbutylbupivacaine
has been measured in the blood or urine. Clearance is 0.47 L/min and the
elimination half time is about 210 minutes.
Routes of administration/ Doses:
Bupivacaine is used for infiltration, peripheral nerve block,
epidural and spinal anesthesia.
Concentration Used:
? Infiltration - 0.25%
? Peripheral  nerve Block - 0.25% - 0.5%
? Epidural Anesthesia - 0.25%-0.5%
? Spinal Anesthesia - 0.5% Heavy
ROPIVACAINE HYDROCHLORIDE
Ropivacaine Hydrochloride is a member of the amino amide class
of local anesthetics and is supplied as the pure S-(-)-
enantiomer. Ropivacaine HCl is chemically described as S-(-)-1-propyl-
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2',6'-pipecoloxylidide hydrochloride monohydrate. The drug substance is
a white crystalline powder, with a molecular formula of
C17H26N2O•HCl•H2O and the following structural formula:
Physico chemical properties:
? Molecular weight - 328.89
? pKa - 8.1
? Protein binding - 94%
? Fraction nonionized % at pH 7.4 -17
Pharmacokinectics:
Ropivacaine is 94% protein bound, mainly to Alpha1-acid
glycoprotein. The lipid solubility is intermediate between lidocaine and
bupivacaine. Volume of distribution is 59 liters. Ropivacaine is
extensively metabolized in the liver, predominantly by aromatic
hydroxylation. It is metabolized to 2,6-pipecoloxylidide and 3-
hydroxyropivacaine by hepatic cytochrome P-450 enzymes. Only a small
fraction of ropivacaine is excreted unchanged in the urine.  Clearance is
0.44 (L/min) and elimination half time is 108 min. Overall, the clearance
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of ropivacaine is higher than that determined for bupivacaine and its
elimination half –time is shorter. The higher clearance of ropivacaine
may offer an advantage over bupivacaine in terms of systemic toxicity.
Presentation:
As a clear solution of 0.25% /0.5%/0.75% Ropivacaine (Naropin)
hydrochloride.
Routes of administration / Doses:
? Infiltration - 2.5 and 5 mg/ml
? Peripheral nerve blockade - 5 and 10 mg/ml
? Epidural - 5 and  7.5 mg/ml
SIDE EFFECTS OF LOCAL ANESTHETICS:
The principal side effects related to the use of local anesthetics are
allergic reactions and systemic toxicity due to excessive plasma
concentrations of the local anesthetic.
Allergic reactions:
Allergic reactions to the amide type local anesthetics are extremely
rare when compared with esters of local anesthetics due to the metabolite
paraaminobenzoic acid. Allergic reaction may also be due to
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methylparaben or similar substances used as preservatives in commercial
preparations of ester and amide local anesthetics.
Systemic toxicity:
Systemic toxicity of local anesthetics is due to an excess plasma
concentration of the drug, accidental intravascular injection.  Systemic
toxicity of local anesthetics involves the central nervous system and
cardiovascular system.
Central nervous System:
The principal effect of Bupivacaine is reversible neural blockade.
This leads to a characteristically biphasic effect in the central nervous
system. During accidental over dosage or direct vascular injections the
clinical signs are numbness of tongue and circumoral tissue, light
headedness, visual and auditory disturbances, muscular twitching and
tremors. Skeletal muscle twitching is often first evident in the face and
extremities and signal immediate tonic- clonic seizures. The signs may
progress to generalized convulsion of the tonic clonic nature. When
plasma levels continue to rise, CNS excitation is rapidly superseded by
depression (drowsiness, disorientation and coma). The typical plasma
concentration of Bupivacaine associated with seizure is 4.5 to 5.5 ug/ml.
In studies which subjected volunteers to continuous intravenous infusions
of ropivacaine and bupivacaine until the onset of CNS symptoms,
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volunteers tolerated a 25% greater total dose of ropivacaine than
bupivacaine, and plasma levels of ropivacaine were greater at onset of
symptoms.90
Cardiovascular System
The cardiovascular system is more resistant to the toxic effects of
high plasma concentrations of local anesthetics than is the CNS.
Bupivacaine is markedly cardiotoxic. It results from blockade of cardiac
sodium channels. At high plasma concentrations sufficient cardiac
sodium channel is blocked so that conduction and automaticity becomes
adversely depressed. Effects of the drug on calcium ion and potassium
ion channels and local anesthetic induced inhibition of cyclic adenosine
monophosphate (cAMP) production may also contribute to cardio
toxicity. Accidental IV injection may result in precipitous hypotension,
cardiac dysrhythmias and atrioventricular heart block. It may cause
ventricular cardiac dysrhythmias through direct brain stem effect.
Cardiotoxic plasma concentration of Bupivacaine is 8-10 ug/ml.
Commercial bupivacaine is a 50:50 racemic mixture of the S- and
R-enantiomers. Because of its greater affinity for and dwell time at
voltage-gated sodium channels, the R configuration confers greater
cardiotoxicity to racemic bupivacaine. Compared to the S-enantiomer,
R-bupivacaine binds three times more firmly to the sodium channel, and
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unbinds 4.4 times as slowly. R-bupivacaine is also more arrhythmogenic,
and slows ventricular conduction 4.6 times as much as S-bupivacaine.
Ropivacaine is manufactured as the pure S-enantiomer in order to take
advantage of the decreased cardiotoxicity of the S-configuration. The
decrease in cardiotoxicity is due to S-ropivacaine's steroselectivity.
USE OF VASOCONSTRICTORS
Epinephrine (1:2,00,000 or 5µg/ml)when added to local anesthetic
solution , produce vasoconstriction which limits systemic absorption and
maintains the drug concentration in the vicinity of the nerve fibres to be
anesthetized. Thus it prolongs the duration of block and also by lowering
the peak blood level, it reduces the incidence of systemic toxicity of the
local anaesthetic. Most local anesthetics with the exception of ropivacaine
possess intrinsic vasodilator properties and it is possible that epinephrine
induced vasoconstriction will slow clearance from injection site and thus
prolonging the time the drug is in contact with the nerve fibres.
The extent to which epinephrine prolongs the duration of
anesthesia depends on the specific local anesthetic used and the site of
injection. In addition to decreasing systemic absorption to prolong
conduction blockade, it may also enhance conduction blockade by
increasing neuronal uptake of local anesthetic. The alpha-adrenergic
effects of epinephrine may be associated with some degree of analgesia
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that could contribute to the effects of conduction blockade. The addition
of epinephrine to local anesthetic solution has little, if any, effect on the
onset rate of local analgesia.
Systemic absorption of epinephrine may accentuate systemic
hypertension in vulnerable patients.
EPINEPHRINE
It’s a non selective agonistic of all adrenergic receptor including
alpha1, alpha2, beta1, beta2 and beta3 receptors. Epinephrine is synthesized
in the adrenal gland in an enzymatic pathway that converts amino acid
tyrosine in a series of intermediates and ultimately epinephrine. Tyrosine
is first oxidized to L-dopa, which is subsequently decarboxylated to give
dopamine. Dopamine on oxidation gives norepinephrine, which is
methylated to give epinephrine.
Formula: C9H13 NO3
Functions:
? Regulation of myocardial contractility, heart rate, vascular and
bronchial smooth muscle tone.
? Potentiates glandular secretions and metabolic processes like
glycogenolysis and lipolysis.
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Pharmacokinetics:
Oral administration is not effective because epinephrine is rapidly
metabolized in the gastrointestinal mucosa and liver. Absorption after SC
injection is slow because of local epinephrine induced vasoconstriction.
Epinephrine is poorly lipid soluble, preventing its ready entrance into the
CNS and accounting for the lack of cerebral effects. Half life is 2
minutes.
Clinical uses:
? Addition to local anesthetic solutions to decrease systemic
absorption and prolong the duration of action of the anesthetic
? Treatment of life-threatening allergic reaction
? During cardiopulmonary resuscitation as the single most important
therapeutic drug, and
? Continuous infusion to increase myocardial contractility.
Side effects:
Palpitation, Tachycardia, Anxiety, Headache, Tremors,
Hypertension, Acute pulmonary oedema.
Review of
Literature
30
REVIEW OF LITERATURE
1. A comparison of ropivacaine 0.5% and bupivacaine 0.5% for
brachial plexus block. Anesthesiology. 1991 Apr; 74(4):639-42.
Hickey R, Hoffman J, Ramamurthy S.
Forty-eight patients received a subclavian perivascular brachial
plexus block for upper-extremity surgery. One group (n = 24) received
ropivacaine 0.5% (175 mg) and a second group (n = 24) received
bupivacaine 0.5% (175 mg), both without epinephrine. Onset times for
analgesia and anesthesia in each of the C5 through T1 brachial plexus
dermatomes did not differ significantly between groups. Duration of
analgesia and anesthesia was long (mean duration of analgesia, 13-14 h;
mean duration of anesthesia, 9-11 h) and also did not differ significantly
between groups. Motor block was profound, with shoulder paralysis as
well as hand paresis developing in all of the patients in both groups. Two
patients in each group required supplemental blocks before surgery.
Conclusion: Ropivacaine 0.5% and bupivacaine 0.5% appeared equally
effective in providing brachial plexus anesthesia.
2. 0.75% and 0.5% ropivacaine for axillary brachial plexus block: A
clinical comparison with 0.5% bupivacaine. Reg Anesth Pain Med
1999; 24:514-8. Laura Bertini M.D, Vincenzo Tagariello M.D.,
Stefania Mancini M.D., et al
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It’s a double blinded , randomized , prospective study . 32 mL of
the local anesthetic solution into the midaxilla, by a nerve-stimulator
technique. The rate of complete sensory and motor block observed with
both ropivacaine groups was higher at 10, 15, and 20 minutes post
injection (P < .001). The mean peak time was shorter with ropivacaine
than with bupivacaine (R50 = 16.37 minutes, R75 = 14.7 minutes, B =
22.3 minutes, P < .05). The quality of the anesthesia was higher with
ropivacaine, as measured by the intraoperative needs for opioids and the
overall patient's satisfaction (P < .05). Conclusions: Ropivacaine showed
advantages over bupivacaine for axillary brachial plexus block. Because
no statistical differences were found between the two ropivacaine groups,
we therefore conclude that 0.75% does not add benefit and that 0.5%
ropivacaine should be used to perform axillary brachial plexus blocks.
3. Brachial plexus block with a new local anaesthetic: 0.5 per cent
ropivacaine. Can J Anaesth. 1990 Oct; 37(7):732-8. Hickey R,
Candido KD, Ramamurthy S, Winnie AP et al
0.5 % ropivacaine was used in 32 patients receiving a subclavian
perivascular block for upper extremity surgery. One group (n = 15)
received 0.5 per cent ropivacaine without epinephrine and a second group
(n = 17) received 0.5 per cent ropivacaine with epinephrine in a
concentration of 1:200,000. Anaesthesia was achieved in 87 per cent of
the patients in both groups in all of the C5 through T1 brachial plexus
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dermatomes. Motor block was profound with 100 per cent of patients in
both groups developing paresis at both the shoulder and hand and 100 per
cent developing paralysis at the shoulder. There was a rapid initial onset
of sensory block (a mean of less than four minutes for analgesia) with a
prolonged duration (a mean of greater than 13 hr of analgesia). The
addition of epinephrine did not significantly affect the quality or onset of
sensory or motor block. The duration of sensory block was reduced by
epinephrine at T1 for analgesia and at C7, C8, and T1 for anaesthesia.
The duration of sensory block in the remaining brachial plexus
dermatomes as well as the duration of motor block was not affected by
epinephrine. There was no evidence of cardiovascular or central nervous
system toxicity in either group with a mean dose of 2.5-2.6 mg/kg
ropivacaine.
4. Comparison of S (-) Bupivacaine and racemic (RS) - bupivacaine
in supraclavicular brachial plexus block. BJA 1998; 80:594- 598. C.R
Cox, M.R. Checketts, N. Mackenzie, N.B.Scott et al
This study compared S (-) Bupivacaine with racemic RS -
bupivacaine in supraclavicular brachial plexus block in 75 patients
undergoing elective hand surgery. Patients received 0.4 ml/kg of either
0.25% or 0.5% S (-) bupivacaine or 0.5% RS bupivacaine in a
randomized double blind study. There were no significant differences in
onset time, dermatomal spread or duration of sensory and motor block
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between three groups. Duration of sensory block was prolonged with
wide inter- patient variation. Conclusion: S (-) bupivacaine was suitable
for local anesthetic use in brachial plexus block.
5. A comparative study of 0.25% ropivacaine and 0.25% bupivacaine
for brachial plexus block. Anesth-Analg. 1992 Oct. 75(4) 602-6.
Hickey.R,Rowley.C.L, Ramamurthy.S, Winnie.A.P et al
The randomized double blind study compares the effectiveness of
0.25% ropivacaine and 0.25% bupivacaine in 44 patients receiving a
subclavian perivascular brachial plexus block for upper extremity
surgery.. Onset times for analgesia and anesthesia did not differ
significantly between the two groups.  The  mean  onset  time  for  analgesia
ranged from 11.2 to 20.2 min, and the mean onset time for anesthesia
ranged from 23.3 to 48.2 min. The onset of motor block differed only
with respect to paresis in the hand, with bupivacaine demonstrating a
shorter onset time than ropivacaine. The duration of sensory and motor
block also was not significantly different between the two groups. The
mean duration of analgesia ranged from 9.2 to 13.0 h, and the mean
duration of anesthesia ranged from 5.0 to 10.2 h. Both groups required
supplementation with peripheral nerve blocks or general anesthesia in a
large number of cases. Conclusion: In view of the frequent need for
supplementation noted with both 0.25% ropivacaine and 0.25%
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bupivacaine, we do not recommend using the 0.25% concentrations of
these local anesthetics to provide brachial plexus block.
6. A Comparison of 0.5% Bupivacaine, 0.5% Ropivacaine, and
0.75% Ropivacaine for Interscalene Brachial Plexus Block. Anesth
Analg 1998; 87:1316-9. Stephen M. Klein, Roy A. Greengrass, Susan
M. Steele, Fran J. D’Ercole, Kevin P. Speer, David H. Gleason, et al
Seventy-five adult patients were entered into this double-blind,
randomized study. Patients were assigned (n = 25 per group) to receive an
interscalene block using 30 ml of 0.5% bupivacaine, 0.5% ropivacaine, or
0.75% ropivacaine. All solutions contained fresh epinephrine in a
1:400,000 concentration. The mean onset time of both motor and sensory
blockade was <6 min in all groups. Duration of sensory blockade was
similar in all groups as defined by the three recovery measures.
Conclusion: There is no clinically important difference in times to onset
and recovery of interscalene block for Bupivacaine 0.5%, ropivacaine
0.5%, and ropivacaine 0.75% when injected in equal volumes. In
addition, increasing the concentration of ropivacaine from 0.5% to 0.75%
fails to improve the onset or duration of interscalene brachial plexus
block.
7. A clinical comparison of ropivacaine 0.75%, ropivacaine 1% or
bupivacaine 0.5% for interscalene brachial plexus anaesthesia.
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European Journal of Anaesthesiology (1999), 16: 11: 784-789. A
Casati, G Fanelli, G. Cappelleri, P. Beccari, L.Magistris, et al
45 patients, undergoing elective shoulder surgery, were randomly
allocated to receive interscalene brachial plexus anaesthesia with 20 mL
of either ropivacaine 0.75% (n=15), ropivacaine 1% (n=15), or
bupivacaine 0.5% (n=15). Readiness for surgery was achieved later with
bupivacaine 0.5% (28±15 min) than with ropivacaine 1% (10±5 min)
(P=0.005) and ropivacaine 0.75% (15±8 min) (P=0.0005). 7 patients
receiving bupivacaine 0.5% required intra-operative analgesic
supplementation (fentanyl 0.1 mg intravenous) compared with one patient
receiving ropivacaine 0.75%, and two patients treated with ropivacaine
1% (P=0.02). The time from the block placement to first request for pain
medication was similar in the three groups. Conclusion: 0.75% or 1%
ropivacaine allows for a prolonged post-operative pain relief, similar to
that provided by bupivacaine 0.5%, with short onset time of surgical
anaesthesia.
8. A Clinical and Pharmacokinetic Comparison of Ropivacaine and
Bupivacaine in Axillary Plexus Block. Anesth Analg 1995; 81:534-8.
Vilho A. Vainionpaa G et al
The clinical and pharmacokinetic properties of ropivacaine and
bupivacaine, both 5 mg/mL, used in axillary plexus block were compared
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in 60 patients in this randomized, double-blind, parallel-group study. The
axillary plexus was identified with a nerve stimulator and 30, 35, or 40
mL of drug, depending on body weight, was injected into the perivascular
sheath. In 20 patients, venous blood samples for the pharmacokinetic
measurement were obtained over 24 h. The median onset time for
anesthesia and complete motor block were in the range of 12-48 min and
5-20 min, respectively. Thirty-eight percent of patients in the ropivacaine
group and 29% in the bupivacaine group needed additional nerve block(s)
or supplementary analgesia and 7% in the bupivacaine group needed
general anesthesia for surgery. Anesthesia was achieved in 52%-86% of
the evaluated six nerves in the ropivacaine group and in 36%-87% in the
bupivacaine group; the lowest figures were seen in the musculocutaneous
nerve. In the pharmacokinetic study the mean peak plasma concentrations
were 1.28+/- 0.21 mg/L in the ropivacaine group and 1.28 +/-0.47 mg/L
in the bupivacaine group and the median times to peak plasma
concentration were 0.86 h and 0.96 h, respectively. Conclusion: No
statistically significant differences were found between ropivacaine and
bupivacaine in either the clinical or the pharmacokinetic comparisons.
9. Plasma concentrations of ropivacaine given with or without
epinephrine for brachial plexus block. Can J Anaesth 1990 / 37:8 /
pp878-82.  Rosemary Hickey, Janna Blanchard, Joan Hoffman, Jan
Sjovall, Somayaji Ramamurthy.
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Single injection of 33 ml ropivacaine for subclavian perivascular
block and 5 ml to block the intercostobrachial nerve in the axilla was
given. One group (n = 8) received 0.5 per cent ropivacaine without
epinephrine and the other (n = 9) received 0.5 per cent ropivacaine with
epinephrine 1:200,000. Plasma ropivacaine concentrations were measured
from peripheral venous blood samples taken for 12 hr after drug
administration. The mean peak plasma concentration was 1.6 +/- 0.6 mg/
L  and  1.3  +/- 0.4 mg /L after administration of ropivacaine with and
without epinephrine. The median time to peak plasma concentration was
0.75 hr and 0.88 hr. The differences were not statistically significant.
Conclusion: Addition of epinephrine does not alter tire pharmacokinetic
properties of ropivacaine when used for subclavian perivascular brachial
plexus block.
10. Epinephrine Does Not Prolong the Analgesia of 20 mL
Ropivacaine 0.5% or 0.2% in a Femoral Three-In-One Block.
Anesth Analg. 1988 Nov; 67(11):1053-8. Anne Weber, Roxane
Fournier, Elisabeth Van Gessel, Nicolas Riand et al
41 patients undergoing total knee replacement under combined
peripheral block/general anesthesia were randomly allocated to two
groups. After insertion of a femoral catheter, 21 patients in the
Ropivacaine-Epinephrine (ROPI-EPI) group received 20 mL ropivacaine
0.5% plus epinephrine 1:200,000, whereas 20 patients in the Ropivacaine
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group (ROPI) received 20 mL plain ropivacaine 0.5%. Thereafter, a
sciatic block with 30 mL bupivacaine 0.5% plus epinephrine 1:200,000
was performed in all patients, followed by general anesthesia. After
surgery, patient-controlled analgesia (PCA) with ropivacaine 0.2% plus
epinephrine 1:200,000 for Group ROPI-EPI and plain ropivacaine 0.2%
for Group ROPI was available via the femoral catheter (200 mL
ropivacaine 0.2% ± epinephrine, bolus 20 mL, lockout 120 min). The
interval between the initial ropivacaine injection and the first PCA
injection determined the duration of 20 mL ropivacaine 0.5% ±
epinephrine, whereas the interval between the first and second PCA
injection determined the duration of 20 mL ropivacaine 0.2% ±
epinephrine. The average duration of ropivacaine 0.5% was 657 ± 345
min for the ROPI-EPI group and 718 ± 423 min for the ROPI group (NS),
whereas for ropivacaine 0.2%, the average duration was 409 ± 245 min
for the ROPI-EPI group and 419 ± 339 min for the ROPI group (not
significant). Conclusion: We conclude that epinephrine does not
influence the duration of analgesia of the ropivacaine concentrations
investigated.
11. High-dose bupivacaine, levobupivacaine and ropivacaine in
axillary brachial plexus block. Acta Anaesthesiologica Scandinavica
[2004, 48(5):601-6]. Liisanantti O, Luukkonen J, Rosenberg PH
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In 90 patients scheduled for hand and forearm surgery, a
perivascular axillary brachial plexus block was performed with 45 ml of 5
mg ml of either racemic bupivacaine-HCl, levobupivacaine-HCl, or
ropivacaine-HCl. After similar onsets of sensory block, the sum of
completely anaesthetized innervation areas of the four main nerves at 45
min was greater in the ropivacaine group than in the levobupivacaine
group (P < 0.01). Complete motor block at the elbow was more frequent
in the ropivacaine group (67%) than in the bupivacaine (47%) and
levobupivacaine groups (30%).In the hand, the corresponding results
were 83%, 77%, and 57%, respectively. Mean duration of the blocks was
similar in the bupivacaine, levobupivacaine and ropivacaine groups at
19.3 h, 19.5 h, and 17.3h, respectively. Conclusion: Ropivacaine-HCl 5
mg /ml produced slightly better sensory and motor block intensity than
the same dose of levobupivacaine-HCl.
12. Ropivacaine: An Update of its Use in Regional Anaesthesia.
Drugs: November 2000 - Volume 60 - Issue 5 - pp 1065-1093.
McClellan, Karen J.; Faulds, Diana
In patients about to undergo upper limb surgery, 30 to 40ml
ropivacaine 0.5% produced brachial plexus anaesthesia broadly similar to
that achieved with equivalent volumes of bupivacaine 0.5%, although the
time to onset of sensory block tended to be faster and the duration of
motor block shorter with ropivacaine. Conclusion: Ropivacaine is a well
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tolerated regional anaesthetic with an efficacy broadly similar to that of
bupivacaine. However, it may be a preferred option because of its
reduced CNS and cardiotoxic potential and its lower propensity for motor
block
13. The place of ropivacaine in anesthesia. Acta Anaesth. Belg., 2003,
54, 141-148. R. STIENSTRA.
Ropivacaine has a lower systemic toxicity than both racemic and
levobupivacaine. Especially its better cardiotoxic profile has been well
documented and is an important advantage when using techniques with a
potential for high plasma concentrations. The lower systemic toxicity of
ropivacaine compared to bupivacaine is not offset by a lower potency, as
ropivacaine in a 50% higher dose is still less cardiotoxic.
14. The subclavian perivascular technique of brachial plexus
anesthesia. Aneathesiology 1964; 25:353-363. Winnie A, Collins V
The prevertebral fascia envelops the brachial plexus from the
cervical vertebrae to the distal axilla, forming a subclavian perivascular
space that is continuous with the axillary perivascular space. By applying
the concept of the axillary perivascular technique to the supraclavicular
approach, subclavian perivascular technique was developed which affords
greater simplicity, safety and consistency of results. Once the space is
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entered a single injection is necessary and the extent of anesthesia will
depend on the volume of anesthetic and the level at which it is injected.
15. The Supraclavicular Block with a Nerve Stimulator: To Decrease
or  Not  to  Decrease,  That  Is  the Question. Anesth Analg 2004;
98:1167–71. Carlo D. Franco, Vitaliy Domashevich, Gennadiy
Voronov, Amir B. Rafizad, and Tanyu J. Jelev
This study concluded that during the performance of  a
supraclavicular block eliciting a clearly visible response of the fingers at
0.9 mA can be immediately followed by the injection of local anesthetic,
because decreasing the output to 0.5 mA does not seem to improve the
overall quality of the block as measured by the onset and duration of
anesthesia or patient satisfaction.
Material and
Methods
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MATERIALS AND METHODS
This is a prospective randomized double blinded study conducted
at Government Stanley Hospital, attached to Stanley Medical College,
Chennai from April 2010 to October 2010 after approval by the
departmental dissertation committee and the hospital’s ethical committee.
Seventy five patients of ASA grade I or II of either sex undergoing plastic
surgery (both elective and emergency) on forearm or hand were randomly
allocated into three groups. Each group comprises of 25 patients.
Inclusion criteria:
? Age 18 - 45 yrs
? Sex (Male/ Female)
? Weight (50-65 kg)
? ASA grade I & II scheduled to undergo forearm and hand
surgery under subclavian perivascular brachial plexus block
Exclusion criteria
? Coagulopathy
? Infection at the puncture site
? Hypertension
? Diabetes mellitus
? Allergy to amide local anesthetics
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? Pregnancy
? Severe pulmonary pathology
? Mental incapacity or language barrier
? BMI more than 35
? Anatomical variations
Drugs and Equipment:
? Oxygen source
? BRAUN –Stimuplex DIG – Nerve locator
? Disposable Braun – Stimuplex (insulated) needle
A50(22Gx2”)
? 0.5 % Bupivacaine and 0.5% Ropivacaine
? Epinephrine (1:2,00,000)
? Midazolam and Fentanyl injection
? Appropriate size intravenous cannula and IV fluids
? Standard monitors
? Airway equipments
? All emergency drugs.
Procedure
All patients were preoperatively evaluated for any systemic
diseases and investigations done prior to assessment. Procedure was
DRUGS
EQUIPMENTS
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explained in detail and written consent was obtained. Procedure was
carried out in theatre where facilities for resuscitation were available.
After obtaining informed consent, patients were randomly assigned
to receive 30 ml of one of three different solutions.
? GROUP I – Receives 0.5 % Ropivacaine without epinephrine.
? GROUP II-Receives 0.5% Ropivacaine with epinephrine
(1:2,00,000)
? GROUP III – Receives 0.5% bupivacaine.
0.5% ropivacaine was prepared by adding 10 ml of distilled water
to 20 cc of 0.75% ropivacaine (ROPIN 0.75% - 7.5 mg/l, Preservative
free 20 ml amp). Epinephrine is available as 1 mg in 1ml amp. 9 ml of
distilled water is added to it thus each ml now contains 100 micro
gram.1.5 ml of this is added along with 8.5 ml of distilled water to
available 0.75% ropivacaine to get 30 ml of 0.5% Ropivacaine with
epinephrine(1:2,00,000).The randomization involved the use of sealed
envelopes. A sealed envelope was randomly selected by the patient and
opened by an assistant, with instructions to draw up the relevant drug.
The syringe was labelled with the patient’s name and it was handed to the
investigator.
All patients were brought to preoperative holding area. After
connecting monitors to the patient, Intravenous line was started for all the
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patients in the contralateral arm with 18G intravenous cannula and IV
fluid was started. Patient was sedated with IV Midazolam 0.01 to 0.02
mg/kg and Fentanyl 1 to 2 microgram / kg. Each patient received
subclavian perivascular brachial plexus block using nerve locator.
SUBCLAVIAN PERIVASCULAR BRACHIAL PLEXUS BLOCK:
Patient was placed on the table and proper illumination was done
at the site of block.
POSITION:
? Patient was placed in supine position with head turned 30? to the
opposite side to be injected.
? The arms were placed at the patient’s side with hands pointing
towards the knee. The arm on the side to be injected may be pulled
to depress the clavicle and the shoulder.
? A rolled towel was placed lengthwise between the shoulders along
the spine to give the best exposure of the area.
STEPS:
The block site was aseptically prepared and draped.
? The anesthesiologist stands at the head end of the table.
NEEDLE INSERTION FOR SUBCLAVIAN PERIVASCULAR BLOCK
FINGER AND THUMB FLEXION - THE IDEAL RESPONSE TO NERVE
STIMULATION
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? The patient was asked to lift the head slightly to bring the
clavicular head of the sternomastoid muscle into prominence.
? The index finger was placed lateral to the muscle and the patient is
asked to relax. The index finger was rolled laterally across the
belly of the muscle until the interscalene groove is palpated.
? Finger was then moved inferiorly down the groove until the pulse
of the subclavian artery was palpated between the scalene
muscles.
? A skin wheal was raised at this point with 2 ml of 2 % lignocaine
with a 24 G needle about 2-3 cms above the midpoint of the
clavicle.
? Pulsation of the subclavian artery against the palpating finger is a
guide to supraclavicular block.
Positive pole of the cable is connected to the patient’s arm on the
side of block. Negative pole of the cable is connected to stimulating block
needle. Injecting syringe with local anesthetic solution is connected with
extension catheter of the block needle. Then, with the nerve stimulator
output set at 0.9 mA at 1 Hz, the needle was inserted just above the
palpating finger and was advanced directly caudad (parallel to the table)
until a desired evoked motor response of flexion or extension of all the
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fingers was obtained, at which point the output was reduced to 0.5 mA. If
the response was still visible at this level of stimulation, the needle is
stabilized and 2-3ml of local anesthetic is injected after a negative
aspiration for blood according to the group
? Group I patient receives 30 ml of 0.5% of ropivacaine without
epinephrine,
? Group II patient receives 30 ml of 0.5% of ropivacaine with
epinephrine (1:2,00,000)
? Group III patient receives 30 ml of 0.5% bupivacaine.
If the needle is in the perivascular space, the volume of the local
anesthetic will produce a “pressure paraesthesia”. The rest of the local
aesthetic should then be injected with frequent aspiration to prevent an
intravascular injection.
? If the needle penetrates the artery it simply indicates that it is too
far anterior.
? The intercostobrachial nerve was blocked separately at the
axilla anterior to the axillary artery by subcutaneous injection of
local anesthetic to ensure complete anesthesia of the upper
extremity
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? The needle should not be advanced beyond 2.5 cm to avoid the
risk of complications (cervical cord injury, pneumothorax,
carotid artery puncture) A cough by the patient is a warning that
the pleura is being irritated by the needle.
After injecting the local anesthetic, the block was tested for both
sensory (using pin prick) and motor (using muscle power). Motor block
was evaluated by thumb abduction (Radial nerve), thumb adduction
(Ulnar nerve), thumb opposition (Median nerve) and flexion of the elbow
in supination and pronation of the forearm (Musculocutaneous nerve).
The following grade was used in the study for assessing sensory and
motor blockade.
Sensory blockade
? Grade 0 = No loss of sensation to pin prick
? Grade 1 = Analgesia (Patient feels touch, but not pain)
? Grade 2 = Anesthesia (Patient does not feel touch)
Motor blockade
? Grade 0 = No weakness
? Grade 1 = Paresis (loss of wrist or elbow flexion)
? Grade 2 = Paralysis (inability to move the limb)
49
Evaluation of sensory and motor function  was carried out prior to
block and then every minute till the onset of blockade and thereafter
every 5  min till one hour and then hourly until complete recovery.
PARAMETERS OBSERVED:
? Onset of sensory blockade: Onset of sensory blockade is
considered when grade 1is achieved.
? Onset of motor blockade: Onset of motor blockade is considered
when grade 1 is achieved.
? Duration of sensory blockade: Duration of sensory blockade is
defined as a time interval between the onset of the sensory
blockade till attainment of grade 0.
? Duration of motor blockade: Duration of the motor block is defined
as the time interval between the onset of motor block till attainment
of grade 0.
? Vital signs: In addition patients is monitored continuously for any
signs of cardiovascular or CNS toxicity. Heart rate, systolic,
diastolic and mean arterial pressure is monitored every ten minutes
for one hour, every 30 min till three hours, every three hours till 12
hours then sixth hourly till 24 hours.
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? Complications (Pneumothorax, accidental vascular puncture,
heamatoma) and side effects (nausea, vomiting, convulsions,
shivering, pruritus, perioral numbness) are looked for.
Statistical analysis:
Data’s like age weight and onset and duration of sensory and motor
block are analyzed using analysis of variance (ANOVA)
Sex is analyzed using Chi square test.
P value <0.05 is taken as statistically siginifcant.
Mean values of hemodynamic parameters ( heart rate, systolic BP,
diastolic BP and Mean arterial BP ) are analyzed over a period of six
hours after giving block. These are compared with the base line values.
Any deviation of more than 30 % from the base line values is considered
as hemodynamic stability 82,83.
Observation &
Results
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OBSERVATION AND RESULTS
In this prospective randomized double blind study we compared
the safety and efficacy of 0.5% Ropivacaine without epinephrine
(group I) and 0.5% Ropivacaine with epinephrine (group II) and 0.5%
Bupivacaine (group III) in patients receiving subclavian perivascular
brachial plexus block in seventy five patients( twenty five in each group).
TABLE 1: AGEWISE COMPARISON
Age Group I Group II Group III
Mean 26.60 27.52 25.32
Range 18-45 18-42 18-45
SD 8.52 7.33 7.57
F value 0.50
p value 0.61(not significant)
The mean age group of patient is 26.60 ± 8.52 SD, 27.52 ± 7.33SD
and 25.32 ± 7.57 SD in group I, group II and group III respectively. The
difference is not significant statistically (p>0.05).
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TABLE 2: SEX DISTRIBUTION
Sex
Group I Group II Group III Total
No % No % No % No %
Male 19 76 14 56 21 84 54 72
Female 06 24 11 44 04 16 21 28
Total 25 100 25 100 25 100 75 100
There are 19 male and 6 females in group I; 14 Males and 11
females in group II and  21  males  and  4  females  in  group  III. p value is
0.08 The sex distribution between groups is not statistically significant
(p >0.05)

53
TABLE3: WEIGHT
Weight
(kg)
Group I Group II Group III
Mean 60.20 60.04 61.40
Range 50-65 50-65 51-65
SD 5.06 5.25 3.70
p value 0.54 (not significant)
The mean weight of patient is 60.20± 5.06 SD, 60.04± 5.25SD
and 61.40± 3.70 SD in group I, group II and group III respectively. The
difference is not significant statistically (p >0.05).
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TABLE 4. ONSET OF SENSORY BLOCK
Onset of sensory block
(min)
Group I Group II Group III
Mean 8.32 8.36 8.40
Range 7-15 5-12 7-10
SD 1.57 1.29 0.82
F value 0.03
p value 0.98 (not significant)
The onset of sensory block is 8.32 min, 8.36 min and 8.40 min
respectively for group I, group II and group III respectively. This is not
statistically significant between groups (p >0.05).
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TABLE 5. ONSET OF MOTOR BLOCK
Onset of motor block
(min)
Group I Group II Group III
Mean 6.84 7.24 6.92
Range 4-11 5-10 4-8
SD 1.34 1.09 1.19
F value 0.76
p value 0.47 (not significant)
The onset of motor block is 6.84 min, 7.24 min and 6.92 min
respectively for group I, group II and group III respectively. This is not
statistically significant between groups (p>0.05).
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TABLE 6. DURATION OF SENSORY BLOCK
Duration of sensory block
(hours)
Group I Group II Group III
Mean 12.96 12.68 13.24
Range 9-15 10-14 12-15
SD 1.37 0.95 0.88
F value 1.66
p value 0.20 (not significant)
The duration of sensory block is 12.96 hours, 12.68 hours and
13.24 hours respectively for group I, group II and group III respectively.
This is not statistically significant between groups (p>0.05).
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TABLE 7. DURATION OF MOTOR BLOCK
Duration of motor block
(hours)
Group I Group II Group III
Mean 13.80 13.56 14.12
Range 11-15 9-15 13-16
SD 0.87 1.26 0.88
F value 1.90
p value 0.16 (not significant)
The duration of motor block is 13.80 hours, 13.56 hours and 14.12
hours respectively for group I, group II and group III respectively. This is
not statistically significant between groups (p >0.05).
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TABLE 8. HEMODYNAMIC PARAMETERS
Parameters
GROUP-I GROUP-II GROUP-III
Mean
over 6
Hours
Base
Line
Deviation
from
Base
Line
Mean
over 6
Hours
Base
Line
Deviation
from
Base
Line
Mean
over 6
Hours
Base
Line
Deviation
from
Base
Line
Heart Rate
bpm
76.44
±4.67
79.84
±5.99
-3.40
±1.32
73.60
±5.03
76.08
±5.76
-2.48
±0.73
75.96
±5.82
79.04
±6.09
-3.08
±0.27
Systolic BP
mm hg
114.8
±6.56
118.65
±7.27
-3.85±
0.71
114.88
±8.02
118.24
±8.39
-3.36
±0.37
115.52
±5.98
120
±6.14
-4.48
±0.16
Diastolic BP
mm hg
73.52
±4.63
77.12
±5.29
-3.85
±1.18
72
±5.29
75.36
±5.16
-3.36
±0.13
71.92
±4.42
78.08
±4.67
-6.16
±0.25
Mean Arterial
Pressure
mm hg
101.08
±5.32
104.88
±6.57
-3.8
±1.25
100.48
±6.28
104.04
±6.79
-3.56
±0.51
101.08
±4.55
106.12
±5.19
-5.04
±0.61
The base line and first six hours mean hemodynamic parameters
(heart rate, systolic and diastolic BP and mean arterial pressure) are
observed during the study period for three groups. From these the
baseline value, mean value over the period of six hours and deviation
from baseline (+ indicates increase, - indicates decrease) values are
derived. There is no hemodynamic instability seen in three groups since
the deviation from baseline is <30 %.
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a) HEART RATE (bpm)
TIME
GROUP-I GROUP-II GROUP-III F-
Value
p
valueMean SD Mean SD Mean SD
0  Minutes 79.84 6.00 76.08 5.76 79.04 6.09 2.77 0.07*
10  Minutes 79.04 6.17 75.60 6.40 77.36 6.24 1.88 0.16*
20  Minutes 78.56 6.34 74.84 4.90 77.48 5.94 4.01 0.07*
30  Minutes 78.20 5.70 74.76 4.58 75.68 6.37 3.67 0.09*
40  Minutes 77.52 5.83 74.12 5.09 75.04 6.28 3.06 0.10*
50  Minutes 77.00 6.96 70.52 14.28 74.08 5.28 2.82 0.07*
1.0 Hours 76.80 6.83 72.96 5.55 73.68 6.03 2.75 0.07*
1.5 Hours 76.88 6.61 73.28 5.07 74.44 5.09 2.66 0.08*
2.0 Hours 76.12 5.70 73.40 4.87 74.88 5.21 1.67 0.20*
2.5 Hours 76.92 5.41 73.40 4.95 74.04 6.09 2.90 0.06*
3.0 Hours 76.40 5.34 73.68 5.15 74.60 6.06 1.57 0.22*
6.0 Hours 76.44 4.67 73.60 5.03 75.96 5.82 2.14 0.13*
* Not significant
Mean heart rate is compared between three groups – baseline and
then for first six hours. Statistically significant difference is not found at
all time period between groups (p>0.05).
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b) SYSTOLIC BLOOD PRESSURE (mm Hg)
TIME
GROUP-I GROUP-II GROUP-III F-
Value
p value
Mean SD Mean SD Mean SD
0  Minutes 118.65 7.27 118.24 8.39 120.00 6.14 0.41 0.67*
10  Minutes 118.08 8.11 117.04 8.68 120.48 5.75 1.34 0.27*
20  Minutes 116.88 7.79 116.40 8.74 120.40 6.46 2.00 0.14*
30  Minutes 115.36 7.27 114.88 8.06 117.92 5.34 1.37 0.26*
40  Minutes 115.04 7.42 114.24 8.39 116.00 5.32 0.38 0.69*
50  Minutes 114.80 7.51 114.80 8.37 115.52 4.81 0.09 0.92*
1.0 Hours 115.12 7.12 114.96 8.61 114.72 5.13 0.02 0.98*
1.5 Hours 114.96 7.21 113.92 8.01 114.64 5.56 0.15 0.87*
2.0 Hours 114.64 7.18 113.92 8.38 114.16 5.16 0.07 0.93*
2.5 Hours 115.36 7.72 113.36 7.25 113.68 5.74 0.60 0.55*
3.0 Hours 114.40 6.90 113.68 8.44 113.84 6.11 0.07 0.93*
6.0 Hours 114.80 6.56 114.88 8.02 115.52 5.98 0.08 0.92*
* Not significant
Mean systolic blood pressure is compared between three groups –
baseline and then for first six hours. Statistically significant difference is
not found at all time period between groups (p>0.05)
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c) DIASTOLIC BLOOD PRESSURE (mm Hg)
Time
GROUP I GROUP II GROUP III F-
Value
p value
Mean SD Mean SD Mean SD
0  Minutes 77.12 5.81 75.36 5.16 78.08 4.67 1.74 0.18 *
10  Minutes 76.64 5.91 75.52 4.87 77.68 5.09 1.04 0.36*
20  Minutes 76.24 6.04 74.80 5.42 77.60 4.32 1.74 0.18*
30  Minutes 74.80 6.66 73.76 5.52 75.76 4.29 0.81 0.45*
40  Minutes 74.24 6.17 73.20 5.42 74.72 4.32 0.53 0.59*
50  Minutes 73.84 5.68 73.20 4.83 74.08 4.64 0.20 0.82*
1.0 Hours 74.00 6.14 73.28 4.16 73.60 4.80 0.13 0.88*
1.5 Hours 73.68 5.50 72.32 5.31 72.72 4.65 0.46 0.64*
2.0 Hours 73.60 4.87 71.76 4.67 72.64 4.61 0.95 0.39*
2.5 Hours 73.60 5.20 71.20 4.24 70.88 4.48 2.55 0.09*
3.0 Hours 73.12 5.29 71.52 5.17 71.92 3.94 0.74 0.48*
6.0 Hours 73.52 4.63 72.00 5.29 71.92 4.42 0.88 0.42*
* Not significant
Mean diastolic blood pressure is compared between three groups –
baseline and then for first six hours. Statistically significant difference is
not found at all time period between groups (p>0.05)
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d) MEAN ARTERIAL BLOOD PRESSURE (mm Hg)
Time
GROUP I GROUP II GROUP III F-
Value
p value
Mean SD Mean SD Mean SD
0  Minutes 104.88 6.57 104.04 6.79 106.12 5.19 0.71 0.50*
10  Minutes 104.32 7.13 103.20 7.08 106.32 4.85 1.50 0.23*
20  Minutes 103.32 7.03 102.52 7.11 106.24 4.89 2.32 0.11*
30  Minutes 101.84 6.75 101.16 6.76 103.96 4.51 1.43 0.25*
40  Minutes 101.52 6.77 100.48 6.87 102.24 4.35 0.52 0.59*
50  Minutes 101.16 6.69 100.96 6.59 101.76 4.02 0.13 0.88*
1.0 Hours 101.32 6.59 101.04 6.64 101.08 4.36 0.12 0.98*
1.5 Hours 101.32 6.44 100.00 6.64 100.64 4.64 0.31 0.74*
2.0 Hours 101.08 6.05 99.84 6.74 100.32 4.25 0.29 0.75*
2.5 Hours 101.52 6.68 99.32 5.90 99.36 4.62 1.18 0.31*
3.0 Hours 100.68 5.91 99.64 7.01 99.84 7.79 0.21 0.81*
6.0 Hours 101.08 5.32 100.48 6.28 101.08 4.55 0.10 0.90*
*Not significant
Mean MAP is compared between three groups – baseline and then
for first six hours. Statistically significant difference is not found at all
time period between groups (p>0.05)

Discussion
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DISCUSSION
Brachial plexus blockade offers an excellent alternative technique
to general anesthesia for surgeries involving the upper limb. The
advantages of regional anaesthesia over general anaesthesia are numerous
and have been clearly established. It provides excellent analgesia that can
be extended into the post operative period by utilizing continuous
regional technique, avoidance of opioid-related side-effects (particularly
nausea, vomiting and sedation), avoidance of airway instrumentation,
decrease in post-operative intensity of care, decrease recovery time and
improved patient satisfaction.
Ropivacaine (S-[-]-1 propyl-2’, 6’pipecoloxylidide) is a new long
acting anesthetic structurally closely related to bupivacaine, the
difference being a propyl group instead of a butyl group linked to the
piperidine ring. Contrary to racemic bupivacaine, ropivacaine is supplied
as the pure S-enantiomer. It reportedly has decreased cardiovascular and
central nervous system toxicity compared with bupivacaine 42,67 and it
may have clinical advantages compared with other local anesthetics. The
potency of ropivacaine in terms of sensory and motor block has now been
determined in clinical use. A large number of open and double blind
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studies18,22-26,40,63,65,69-70 have been performed on human volunteer’s and
patients to determine the efficacy and degree of differential block with
ropivacaine compared with bupivacaine in peripheral and central neural
block.
The onset and duration time of ropivacaine for different regional
anesthetic techniques is controversial. In studies comparing bupivacaine
and ropivacaine for brachial plexus block, some studies report shorter
onset time with ropivacaine compared with bupivacaine 68, where as other
studies find similar 65, 69 or longer 70 onset times of ropivacaine compared
with bupivacaine for brachial plexus block.
Several techniques have been used to prolong the duration of
regional anaesthesia. Besides the continuous infusion of local
anaesthetics through catheters and recently opioids as adjuvants to local
anaesthetic solutions, the addition of epinephrine appears to be the most
widely used). The prolongation of action is generally related to local
vasoconstriction which slows down the vascular reabsorption of local
anaesthetics. Vasoconstriction is related to the action of epinephrine on
alpha l-type receptors.
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Thus in this prospective randomized double blind study thus we
compare the safety and efficacy of 0.5% Ropivacaine with adrenaline and
0.5% Ropivacaine without Adrenaline and 0.5% Bupivacaine in patients
receiving subclavian perivascular brachial plexus block in seventy five
patients (twenty five in each group) undergoing plastic surgery (both
elective and emergency) on the forearm or hand. Demographics, onset
and duration of block, hemodynamic changes and complications are
observed and statistically analyzed.
We did a randomization since it eliminates the source of bias in
treatments assignment and it facilitated blinding the type of treatments to
the investigator and participants. This is done by shuffling envelopes
(non- algorithmic randomization).
The technique used in this study is the nerve locator assisted
subclavian perivascular brachial plexus block. It has been shown by Carlo
D Franco et al 74 that the subclavian perivascular technique of brachial
plexus block provides a consistent, reproducible and effective anesthesia
of the upper extremity and that the major reason for the success of this
technique is that the local anesthetic is injected at the point where the
plexus is reduced to its fewest components and size and the sheath is
reduced to its smallest volume.
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Elicitation of paraesthesia to confirm the needle position in nerve
blocks is becoming less popular as it has problems in the form of direct
neuronal damage by the advancing needle, patient discomfort and failure
rates. While using nerve locator as an aid to the nerve blocks, these
problems can be avoided. The nerve stimulator utilized is the Stimuplex
DIG (B.Braun, Allentown PA) a unit found to be accurate in a recent
comparative study 75. Carlo D Franco et al 74 showed in his study that it is
far more important to get the desired response (i.e., flexion or extension
of the fingers at an output of 0.5 to 0.7 mA) than to look for the minimum
output possible in an effort to get closer to the nerve and hence we use 0.5
mA output.
In elderly patients the pharmacologic changes that occur include
are changes in plasma protein binding (?1 glycoprotein level increase and
albumin decrease), changes in body content (decrease in lean body mass,
increase in body fat and decrease in total body water), changes in drug
metabolism (alterations in hepatic and renal clearance) and changes in
pharmacodynamics. There is a decrease in the number and density of
nerve fibers, a degeneration of axons, and an increase in motor unit action
potentials with increased age 86. The effect of these changes was
demonstrated by Dorfman and Bosley 87, who measured sensory and
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motor conduction velocities of peripheral (median) nerves in elderly
individuals and found an age-dependent decrease in conduction velocity
of both and sensory fibers.In children immaturity of enzyme pathways
and their replacement by other biochemical pathway and changes in
pharmacokinetic parameters due to changes in protein binding and
variation of body fluid distribution exists. Hence elderly and paediatric
patients are excluded in this study.
Carlo D Franco et al74 identified obesity as a possible factor
contributing to either an incomplete or failed block. In patients with
underlying pulmonary disease or in morbidly obese patients,
pneumothorax and unilateral phrenic nerve block can cause severe
symptoms of dyspnoea and lead to significant pulmonary compromise.
Juliann T et al 89 in his study concluded that High BMI and ASA IV are
independent risk factors for block failure in regional anesthesia technique.
Hence we excluded obese patients and patients with severe pulmonary
disease, ASA III and IV in our study. The patients on anticoagulation are
excluded because if vascular puncture is encountered, the expanding
hematoma could compress the airway and it will be difficult to access and
maintain the airway 76.
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Clinical reports have observed unexpectedly high stimulation
thresholds in diabetic patients, even when ultrasound imaging shows
contact of the needle with the nerve.77Conduction velocity in diabetics is
slowed because of numerous factors78 attributable to disrupted neuronal
metabolism and reduced endoneurial blood flow.80 Because longitudinal
conduction of action potentials represents sequential excitation of
segments of neuronal membrane, factors that diminish conduction
velocity would also depress excitation by an external source of
depolarization such as a needle electrode. Reduced excitability of
peripheral nerves by depolarizing current has been confirmed in diabetics
by clinical electrophysiologic examination.79 Particularly important
aspects of diabetic neuropathy are directly attributable to the effect of
hyperglycemia via increased activity of the sorbitol pathway of glucose
metabolism, which is activated in sensory neurons within hours of
exposure to hyperglycemia and produces excitability deficits and sensory
neuron dysfunction within 1–4 weeks.81 Because of above said factors
we excluded patients with diabetes mellitus. Vasoconstrictors 88 produce
a cardiac excitatory action which results in an increase in heart rate, force
of contraction and stroke volume. Epinephrine may precipitate significant
elevation in blood pressure (inadvertent IV injection).Hence
hypertensive patients are excluded from our study.
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During pregnancy increased sensitivity84 (more rapid onset of
conduction) may be present and alterations in protein binding
characteristic of bupivacaine may result in increased concentrations of
pharmacologically active unbound drug in the plasma 85. Hence we
consider pregnancy as exclusion criteria.
The efficacy of 0.25% ropivacaine in subclavian brachial plexus
block has been studied by Hickey et al 70 and it has been shown that it
needed frequent supplementation with peripheral nerve block or general
anesthesia in a large number of patients. Hence we did not choose 0.25%
ropivacaine. In the study by Stephen M Klein et al 23 and Laura Bertini et
al 63, increasing concentration of ropivacaine from 0.5% to 0.75% does
not add benefit and it failed to improve the onset and duration of brachial
plexus block. The use of increasing concentrations of local anesthetic
solutions causes rapid increases in the blood serum level of the local
anesthetic and the slope of the increase plays a significant role in the
severity of toxic manifestations. Furthermore, the percentage that is
protein-bound decreases as the blood serum level of local anesthetic
increases, and this can increase the risks during an accidental injection of
these higher concentrations. Hence we choose 0.5% of ropivacaine to be
compared with 0.5% of bupivacaine.
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Because we consider that using different volumes of local
anesthetic drugs to be tested would prejudice results, we use similar
volume (30 ml) of 0.5% ropivacaine and 0.5% bupivacaine. Peak plasma
concentration of local anesthetic depends on many variables, as well as
body weight and in particular it is accepted that the maximum safe dose
of local anesthetic differ according to the injection site. Thus in our study
we compare equal dose and volume of ropivacaine and bupivacaine.
No significant difference in the age, weight and sex ratio is seen in
our study.
There is no significant difference in onset and duration of sensory
and motor block in our study between groups. This is similar to the
results of the study by Hickey R et al 18 (A comparison of ropivacaine
0.5% and bupivacaine 0.5% for brachial plexus block) on 40 patients who
received subclavian perivascular brachial plexus block for upper-
extremity surgery. He concluded that ropivacaine 0.5% and bupivacaine
0.5% were similar in terms of onset and duration of sensory and motor
block.In another study, Hickey R et al 26 compared 0.5% ropivacaine with
epinephrine and 0.5% ropivacaine without epinephrine in 32 patients
receiving a subclavian perivascular block for upper extremity surgery. He
demonstrated that ropivacaine 0.5% is an effective agent for brachial
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plexus anaesthesia and the addition of epinephrine did not significantly
affect the onset and duration of sensory and motor block.
A Comparison of 0.5% Bupivacaine, 0.5% Ropivacaine, and
0.75% Ropivacaine for Interscalene Brachial Plexus Block was done by
Stephen M. Klein25 et al in seventy-five adult patients All solutions
contained fresh epinephrine in a 1:400,000 concentration. He found there
was no clinically important difference in times to onset and recovery of
interscalene block. Vainionpaa et al 65in his study compared the clinical
and pharmacokinetic properties of ropivacaine and bupivacaine (both 5
mg/mL) used in axillary plexus in 60 patients. He concluded that no
statistically significant differences were found between ropivacaine and
bupivacaine in either the clinical or the pharmacokinetic comparisons.
The rapidity of onset of anesthesia after injection of a local
anesthetic solution into tissues around a peripheral nerve depends on the
pKa of the drug (The pK determines the amount of local anesthetic that
exists in the active non ionized form at the pH of the tissue. pKa of
ropivacaine and bupivacaine being same - 8.1)
Duration of peripheral nerve block anesthesia depends on the dose
of local anesthetic, its lipid solubility, its degree of protein binding,
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concentration and use of vasoconstrictor. Ropivacaine seems to increase
vascular smooth muscle activity and decreases blood flow at the site of
injection over a wider range of concentration compared with
bupivacaine19. Kopacz et al 21 who found that unlike bupivacaine, which
produced cutaneous vasodilatation, ropivacaine produced
vasoconstriction and a reduction of cutaneous blood flow in pigs. When
epinephrine was added to ropivacaine no further reduction in blood flow
was seen whereas when added to bupivacaine it reduced blood flow, thus
showing that addition of epinephrine to ropivacaine would have less
effect on its onset and duration as shown in our study.
Heart rate, systolic, diastolic and mean arterial blood
pressure are monitored. No hemodynamic instability is noted in the
groups after block. One patient in group I and one in group III had failed
block and converted to general anesthesia. These patients’ data are not
included in the study. No block complication is observed in our study and
no supplementation was required .Adverse event seen is nausea (one
patient in group I and one in group III) and vomiting (one patient in group
III). No systemic toxicity is noted.
Summary
73
SUMMARY
This prospective randomized double blind study compared the
safety and efficacy of 0.5% ropivacaine without epinephrine, 0.5%
ropivacaine with epinephrine (1:2,00,000) and 0.5% bupivacaine in
patients receiving subclavian perivascular brachial plexus block using
nerve locator for surgeries on forearm and hand( both elective and
emergency). Seventy five patients are included in the study, they are
divided in to three groups.
i. Group I (n=25) receiving 30 ml 0f 0.5% ropivacaine without
epinephrine.
ii. Group II (n=25) receiving 30 ml of 0.5% ropivacaine with
epinephrine.
iii. Group III (n=25) receiving 30 ml of 0.5% bupivacaine.
After local anesthetic injection following parameters are observed.
i. Time of onset of sensory block.
ii. Time of onset of motor block.
iii. Duration of sensory block.
iv. Duration of motor block.
v. Vital parameters.
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All the three groups are comparable in the distribution of age, sex
and weight. The onset and duration of sensory block did not differ
significantly between the groups. Similarly there is not statistically
significant difference between the groups in onset and duration of motor
block. The addition of epinephrine did not significantly affect the onset
and duration of sensory and motor block of 0.5% ropivacaine.
No hemodynamic instability is observed after the block in all the
groups during the study period. There is no evidence of cardiovascular or
central nervous system toxicity in the study groups with the dose of local
anesthetic used in our study.
Hence, Ropivacaine, a relatively new local anesthetic at a
concentration of 0.5% is equally effective as 0.5% Bupivacaine. With the
theoretical advantage of lesser cardiotoxicity than Bupivacaine,
Ropivacaine may probably be a more safer drug than Bupivacaine in
patients receiving subclavian perivascular brachial plexus block.
Conclusion
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CONCLUSION
In conclusion, 0.5% ropivacaine and 0.5% bupivacaine are found
to be equally efficacious in terms of onset and duration of sensory and
motor block for subclavian perivascular brachial plexus block. The
addition of epinephrine to ropivacaine does not reduce the onset time or
prolong the duration of sensory and motor block. There is no evidence of
cardiovascular or central nervous system toxicity in all groups with the
dose administered in the study. Thus, the selection of the optimal long
acting local anesthetic for peripheral nerve block must take into
consideration of the available local anesthetics, time to onset, duration of
blockade and side effects of each drug and dose. Since it has been shown
that efficacy of 0.5% ropivacaine and 0.5% bupivacaine is same and
ropivacaine has a theoretical advantage of lesser cardiotoxicity over
bupivacaine, it may offer clinical advantage.
Annexure
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PROFORMA
Date                                   :                                          Serial No   :
Name                                 :                                          Weight      :
Age / Sex                           :
IP Number                          :
Diagnosis                            :
Surgery planned                 :
ASA status                         :
Shifted to OT time              :                                       IV access :
Monitors                             :                                       Baseline
Block time                          :                                       HR    :
Surgery starting time          :                                       BP     :
Surgery ending time           :                                       SPO2:
PARAMETERS OBSERVED:
? Onset of sensory block             -   _________
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1 I Srinivasan 26 M 19684 62 Brachydactyl - right Release 8 6 14 13 Nil
2 I Venkatesh 45 M 19720 60 Post Hansen’s sequelae-left Arthodesis – PIP joint 8 8 13 15 Nil
3 I Kumar 18 M 19658 58 Crush injury- right hand Shortening & closure 7 7 13 14 Nil
4 II Raganathan 34 M 19659 64 PTRA-Left hand SSG 7 6 11 13 Nil
5 II Sasikala 26 F 19688 54 PTRA- Right hand Debridement 10 10 14 14 Nil
6 II Niyamath 22 M 19642 65 PTRA-Left hand Wound debridement 9 8 13 13 Nil
7 II Shruthi 20 F 19777 50 Post burn scar over wrist joint Excision 9 8 14 12 Nil
8 III Sasikala 26 F 19758 55 PTRA- right hand Debridement 7 5 12 14 Nil
9 I Raviraja 27 M 19702 65 PTRA – left hand Wound debridemant 7 6 11 13 Nil
10 I Kasi 35 M 19738 65 PTRA right thumb SSG 8 7 15 14 Nil
11 II Moumina 18 F 19804 60 PBSC finger- right hand Release 7 5 12 15 Nil
12 I Anavoo 45 M 19784 65 PTRA- right hand SSG 8 4 14 14 Nil
13 I Sajitha 23 F 19688 50 PTRA- right hand SSG 9 8 15 14 Nil
14 III Pradeep 18 M 19696 63 Raw area left hand SSG 9 6 13 14 Nil
15 III Muchagandhi 18 M 19724 64 PTS- right index Rotational osteotomy 9 8 13 14 Nil
16 III Manivannan 20 M 19920 65 PTRA- left hand Debridement 8 8 13 13 Nil
17 II Pradeepa 28 F 19958 63 Raw area- left hand SSG 9 8 13 14 Nil
18 III Karthi 21 M 19968 58 PB gangrene- left hand Shortening and closure 9 7 13 15 Nil
19 II Aparna 19 F 19928 60 PBSC left index finger Release 9 8 13 14 Nil
20 III Devaraj 20 M 19978 65 PTRA right hand Debridement 8 8 13 13 Nil
S.
nu
m
be
r
G
ro
up
N
am
e
A
ge
se
x
IP
 n
um
be
r
W
ei
gh
t
D
ia
gn
os
is
Su
rg
er
y
O
ns
et
 o
f s
en
so
ry
bl
oc
k 
 (m
in
)
O
ns
et
 o
f m
ot
or
 b
lo
ck
(m
in
)
D
ur
at
io
n 
of
 s
en
so
ry
bl
oc
k 
(h
ou
rs
)
D
ur
at
io
n 
of
 m
ot
or
bl
oc
k 
(h
ou
rs
)
Co
m
pl
ic
at
io
n
21 III Rajeshwari 24 F 20012 64 Crush injury right hand Wound debridement 9 8 14 14 Nil
22 I Praveen 18 M 20019 62 Cruch injury right hand Wound debridement 9 7 9 11 Nil
23 II Pikkas 22 M 20102 63 PTRA-right index finger Debridement 8 7 12 14 Nil
24 I Kandasamy 45 M 20137 64 Pt gangrene right index finger Shortening and closure 8 7 13 14 Nil
25 II Arumugam 30 M 20258 64 PTRA right hand Wound debridement 9 8 13 14 Nil
26 III Venkatesan 22 M 20277 65 PT gangrene right index finger Shortening and closure 9 7 13 15 Nil
27 III Anushya 18 F 20428 58 PTRA right hand SSG 7 7 12 14 Nil
28 III Raj 22 M 20297 62 Crush injury right hand Wound debridement 8 8 13 16 Nil
29 II Vasantha 40 F 20388 50 PTS left index finger Sequestrectomy 8 7 12 14 Nil
30 I Thirupathy 20 M 20327 65 Cracker burst injury rt hand Wound debridement 7 6 13 13 Nil
31 III Kasi 37 M 20317 62 PBSC right index finger Release 9 8 13 15 Nil
32 II Guhankumar 18 M 20319 64 PT gangrene right index finger Shortening and closure 9 8 10 13 Nil
33 III Vikkiraj 18 M 20357 50 PBSC left hand Release 9 6 15 15 Nil
34 I Jhansirani 36 F 20372 52 PTS right index finger Scar excision 8 7 13 14 Nil
35 I Shankar 25 M 20567 62 PTRA right hand SSG 8 6 9 14 Nil
36 II Arumugam 25 M 20569 65 PTRA right hand Shortening and closure 9 7 13 15 Nil
37 I Sandeepkumar 18 M 20618 50 PBSC right index finger Release 8 7 12 15 Nil
38 III Mariya 27 F 20717 58 Lipoma left hand Excision 8 7 12 14 Nil
39 III Selva kumar 20 M 20617 60 Cellulitis right hand Wound debridement 9 7 14 14 Nil
40 III Prabhakaran 31 M 20557 62 Crush injury left thumb Wound debridement 9 5 14 15 Nil
41 I Thilakaraj 23 M 20619 63 Crush injury right hand Wound debridement 7 5 14 14 Nil
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42 II Lingamoorthy 42 M 20719 65 PTRA left hand SSG 8 8 14 14 Nil
43 III Boomilingam 18 M 20779 58 Syndactyl left hand Release and SSG 7 5 12 13 Nil
44 III Manohar 22 M 20801 58 PTRA left index finger Ray amputation 8 6 13 13 Nil
45 I Tamilselvi 19 F 20814 53 PBSC right hand Release 8 11 15 14 Nil
46 II Dineshkumar 19 M 20799 60 Scar contracture rt index
finger
Excision 8 8 13 14 Nil
47 I Nesiya 21 F 20887 52 Syndactyl right hand Release 8 8 14 13 Nil
48 II Divya 18 F 20981 50 Ganglioma left hand Excision 5 6 14 15 Nil
49 III Srinivasan 30 M 20988 65 PTRA right hand Wound debridement 8 8 14 14 Nil
50 III Ramesh 18 M 20908 65 PTRA left index finger Debridement 7 4 14 13 Nil
51 II Girish 32 M 20915 62 PTS gangrene right thumb Wound debridement 8 5 13 14 Nil
52 I Rajesh 19 M 20927 60 Raw area left hand Wound debridement 15 7 13 14 Nil
53 I Selvi 32 F 20932 56 PTRA left middle finger Wound debridement 8 7 13 15 Nil
54 II Prabhakaran 31 M 20944 62 PTRA left thumb Wound debridement 8 7 12 13 Nil
55 III Sanjay 27 M 20872 65 PTRA left hand Wound debridement 10 8 13 14 Nil
56 III Subramani 30  M 20919 62 PTS left hand Scar release 8 7 14 14 Nil
57 II Tamilselvi 29 F 20976 55 PBSC left index finger Release 7 6 12 14 Nil
58 II Nagaraj 35 M 20918 64 PTRA-right hand Debridement 9 8 13 14 Nil
59 I Kamaraj 23 M 21004 60 PTSC left index,middle&ring
finger
Z plasty 8 7 13 14 Nil
60 I Viswanathan 30  M 21017 62 Trigger finger Release 10 7 13 13 Nil
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61 III Abdul basheer 35 M 21067 60 PTS right hand PIP arthrodesis 9 7 14 16 Nil
62 III Michael raj 40 M 21089 65 PTRA left hand Debridement 9 8 13 15 Nil
63 I Pandian 25 M 21172 65 PTRA left hand Debridement 9 8 13 14 Nil
64 I Om Prakash 25 M 21169 64 PTRA right hand Wound debridement 7 5 12 13 Nil
65 II Munirathinam 32 F 21158 61 PBSC left hand Release 12 7 13 13 Nil
66 II Lakshmi 39 F 21192 56 PTRA middle finger Wound debridement 9 8 12 12 Nil
67 II Revathy 19 F 21204 52 PTS right hand Release 9 7 13 13 Nil
68 III Kuppusamy 45 M 21214 60 PT amputation left middle
finger
Shortening and closure 8 7 15 13 Nil
69 I Ganesh 21 M 21219 64 Trigger thumb Release 8 6 13 14 Nil
70 I Anjali 25 F 21234 62 Soft tissue tumour left hand Excision biopsy 8 6 11 15 Nil
71 I Tamilselvan 21 M 21278 64 PBSC left finger Release 9 8 12 14 Nil
72 III Michealraj 26 M 21297 64 PTRA left hand Wound debridement 9 8 12 14 Nil
73 II Perumal 30 M 21304 65 PTRA left hand Wound debridement 8 7 13 15 Nil
74 II Newton 30 M 21322 65 Crush injury left hand Wound debridement 7 7 12 9 Nil
75 II Saravanan 30 M 21405 62 PTRA right hand Debridement 8 7 13 14 Nil
S.NO GROUP PATIENT NAME
HEART RATE (bpm)  SYSTOLIC BLOOD PRESSURE  (mmHg)
0 10 20 30 40 50 1 1.5 2 2.5 3 6 0 10 20 30 40 50 1 1.5 2 2.5 3 6
minutes hours minutes Hours
1 I srinivasan 70 72 68 74 66 66 65 68 68 68 65 70 110 108 104 102 104 106 108 106 108 108 110 112
2 I Venkatesh 74 74 74 72 72 72 70 70 70 71 72 74 120 118 118 118 116 118 120 122 124 126 118 120
3 I Kumar.s 88 88 88 86 87 89 85 86 84 84 83 84 128 124 120 116 116 118 116 116 116 116 118 118
4 II Ranganathan 70 70 72 70 72 70 70 68 68 70 66 70 126 124 124 124 126 126 128 120 120 120 126 122
5 II sasikala 74 76 74 74 72 74 70 70 70 72 70 72 110 108 108 108 110 110 110 106 108 106 106 110
6 II Niyamath 68 64 68 70 66 68 70 70 70 72 68 66 120 118 120 116 116 118 120 122 128 124 124 128
7 II shruthi 70 70 70 70 68 68 66 68 68 70 68 66 106 106 104 104 102 102 104 104 102 106 102 108
8 III Sasikala 88 86 84 82 80 80 84 82 82 82 84 80 110 110 108 110 110 118 108 106 106 108 108 106
9 I raviraja 86 84 82 82 84 86 84 82 78 80 80 84 120 120 118 118 118 118 120 116 116 118 118 116
10 I kasi 72 72 72 74 70 68 68 66 70 75 76 74 120 120 120 118 118 118 118 120 122 122 118 118
11 II Moumina 76 76 74 74 72 70 68 72 72 70 74 72 110 110 108 106 110 112 110 116 106 108 106 108
12 I anavoo 80 82 80 76 74 76 76 74 74 78 75 78 128 130 130 128 126 126 126 126 126 128 126 126
13 I sajitha 86 82 78 78 78 80 80 78 76 74 76 75 110 110 110 108 108 108 106 106 106 110 106 108
14 III Pradeep 78 78 78 74 74 72 70 74 76 72 70 76 120 122 118 120 118 116 118 116 114 114 116 114
15 III Muchagandhi 80 76 80 80 80 74 72 74 74 72 76 78 130 130 130 128 126 126 124 124 124 122 120 126
16 III Manivannan 78 78 78 76 74 72 72 72 70 70 74 72 120 120 118 116 118 116 114 116 116 114 114 114
17 II Pradeepa 80 82 78 78 76 78 72 76 76 76 78 72 120 120 116 116 114 118 114 110 110 114 116 108
18 III Karthik 80 80 80 80 78 76 76 74 72 74 76 78 126 120 124 126 116 118 118 122 118 118 124 120
19 II aparna 72 70 72 72 70 68 69 70 66 65 70 72 110 108 108 106 104 104 108 106 108 108 104 112
20 III Devaraj 80 80 80 80 78 76 76 76 74 74 74 76 122 124 120 120 118 116 116 118 118 120 116 118
21 III Rajeswari 88 88 88 86 86 86 84 84 82 86 84 86 120 122 118 116 114 116 118 114 112 112 110 114
22 I praveen 78 76 78 72 72 72 70 70 72 74 76 74 120 120 118 118 116 116 116 114 114 114 110 110
23 II pikkas 72 70 70 68 70 68 66 66 68 64 68 68 116 116 118 110 116 116 114 108 108 112 110 116
24 I kandasamy 76 74 72 72 70 66 70 70 74 72 72 72 130 134 128 122 120 120 124 122 120 122 122 122
25 II arumugam 78 72 70 72 70 71 71 74 72 74 70 72 130 130 128 122 120 120 122 124 126 126 122 122
26 III Venkateshan 72 72 71 70 70 70 72 68 68 66 66 65 120 120 124 118 118 116 118 112 112 114 110 118
S.NO GROUP NAME
HEART RATE (bpm) SYSTOLIC BLOOD PRESSUR ( mm HG)
0 10 20 30 40 50 1 1.5 2 2.5 3 6 0 10 20 30 40 50 1 1.5 2 2.5 3 6
minutes hours minutes Hours
27 III Anushya 88 88 86 86 84 80 80 80 82 80 78 82 126 126 124 122 118 118 122 120 120 118 120 122
28 III Raj 80 76 76 76 72 72 74 74 75 72 76 76 120 122 118 116 118 116 114 114 116 112 112 118
29 II vasantha 70 72 72 70 68 68 68 66 66 67 70 72 110 108 106 112 104 108 108 110 114 112 116 118
30 I tirupathy 78 78 76 77 76 76 76 74 74 76 76 74 108 108 108 106 106 104 106 106 110 110 108 108
31 III Kasi 70 70 70 68 68 66 66 65 68 66 66 72 110 110 116 108 106 108 106 106 108 104 108 106
32 II guhankumar 80 76 76 76 74 76 74 72 76 76 76 74 120 118 118 116 120 116 118 120 120 116 116 110
33 III Vikkiraj 76 72 72 72 70 70 68 74 78 70 72 74 110 116 110 112 108 106 104 104 106 106 110 112
34 I jhansirani 84 84 80 82 83 86 88 84 82 80 78 78 118 116 116 116 118 118 120 120 116 118 118 114
35 I Shankar 86 84 82 80 84 82 82 86 86 84 84 82 110 108 108 108 106 106 108 108 110 112 112 112
36 I arumugam 78 74 74 76 72 72 72 74 74 75 76 76 130 126 128 126 130 132 128 128 128 126 126 128
37 I sandeepkumar 84 82 84 82 82 78 78 78 76 78 78 76 120 120 116 116 120 122 122 122 118 118 116 116
38 III Mariya 70 68 72 68 64 66 66 68 70 64 66 70 122 118 120 122 118 116 116 118 114 114 118 120
39 III selvakumar 88 84 84 80 78 78 76 78 80 82 78 76 130 130 136 128 120 122 118 122 122 124 124 120
40 III prabhakaran 86 84 84 86 82 82 80 80 76 80 82 86 122 120 126 116 118 116 114 118 114 116 116 118
41 I thilakaraj 86 84 84 84 82 84 82 82 82 84 84 80 126 126 124 124 122 122 122 122 120 120 122 124
42 II lingamoorthy 70 72 72 72 74 70 70 68 72 68 70 70 110 106 108 106 104 106 106 110 110 106 108 108
43 III boomilingam 76 72 72 70 68 74 66 74 72 70 74 74 120 120 126 118 118 116 114 114 112 116 116 114
44 III manohar 84 82 82 84 86 80 81 82 82 78 78 82 124 126 122 122 126 122 118 114 116 118 120 120
45 I tamilselvi 70 68 68 70 72 68 66 66 68 70 72 72 110 110 110 110 108 108 106 106 110 104 106 108
46 II dineshkumar 70 74 76 74 76 76 76 75 78 78 78 74 110 106 108 106 106 108 108 104 106 104 106 108
47 I Nesiya 74 72 70 70 70 68 72 74 74 73 72 74 110 110 106 106 104 106 108 108 106 104 104 104
48 II Divya 76 78 74 74 72 70 74 73 76 76 72 70 110 110 108 106 108 108 104 106 106 104 104 106
49 III srinivasan 70 72 68 66 68 66 67 70 72 68 64 68 110 116 108 108 104 106 106 110 108 108 104 104
50 III Ramesh 80 80 80 76 78 76 78 75 78 80 82 78 118 116 116 118 114 114 112 114 114 116 110 112
51 II Girish 76 74 74 74 74 72 70 74 74 72 70 68 108 106 104 106 104 104 106 106 108 108 106 106
52 I Rajesh 76 72 74 74 76 75 72 74 74 78 69 68 110 108 108 106 108 104 104 106 104 102 100 102
S.NO GROUP NAME
HEART RATE (bpm) SYSTOLIC BLOOD PRESSURE (mm HG)
0 10 20 30 40 50 1 1.5 2 2.5 3 6 0 10 20 30 40 50 1 1.5 2 2.5 3 6
minutes hours minutes Hours
53 I Selvi 80 82 80 84 82 78 78 78 76 78 76 78 120 122 126 118 118 116 114 110 106 106 108 108
54 II prabhakaran 80 80 78 76 76 74 82 82 76 76 78 80 120 122 120 118 116 118 116 110 106 106 108 108
55 III Sanjay 80 76 82 72 74 76 76 78 80 82 76 76 128 128 126 116 120 118 118 120 122 122 124 122
56 III subramani 82 82 80 78 76 76 74 72 78 74 76 80 124 128 124 122 118 116 116 118 114 112 114 122
57 II tamilselvi 80 82 80 78 78 76 76 78 76 75 76 78 118 116 114 116 112 110 108 106 108 106 108 110
58 II Nagaraj 88 86 84 86 87 82 82 80 80 82 84 84 130 128 128 126 124 126 122 124 126 124 130 128
59 I kamaraj 88 88 86 84 82 78 78 78 74 78 78 80 120 120 118 116 114 110 110 108 112 118 118 120
60 I viswanathan 84 84 86 84 80 82 78 76 76 82 86 84 130 128 130 130 130 128 126 124 126 126 120 120
61 III abdul basheer 70 68 68 66 66 70 68 69 68 67 66 68 116 116 118 114 112 110 116 110 112 108 108 116
62 III michael raj 76 70 72 70 74 74 70 68 70 72 73 70 110 110 116 116 110 108 106 104 104 102 102 104
63 I Pandian 70 72 74 70 72 68 68 72 66 64 68 68 118 116 116 114 112 110 114 114 110 112 112 114
64 I Om prakash 88 90 92 88 84 84 82 82 80 78 76 76 130 132 126 118 120 116 116 126 124 126 124 126
65 II munirathinam 80 76 76 76 78 76 74 74 72 74 75 74 126 126 128 124 122 122 124 120 122 120 124 126
66 II lakshmi 74 72 74 74 75 70 74 78 76 78 82 80 120 120 122 120 118 118 120 116 118 114 114 116
67 II revathy 70 72 71 71 69 67 66 66 68 70 68 74 110 110 108 106 104 102 100 104 102 110 104 104
68 III kuppusamy 72 70 70 70 68 66 64 70 65 70 70 70 120 120 124 120 118 116 116 118 118 116 114 118
69 I ganesh 80 82 84 86 84 85 88 90 85 86 84 82 120 120 118 122 126 128 124 122 124 122 122 118
70 I anjali 78 74 76 76 78 80 82 80 78 76 74 76 110 106 106 106 104 106 106 108 104 106 108 110
71 I tamilselvan 80 76 76 78 78 78 82 84 86 82 80 78 118 118 120 120 118 118 118 116 114 116 116 116
72 III michael raj 84 82 80 76 80 74 82 80 80 80 84 86 122 122 120 116 116 118 118 114 114 108 108 110
73 II perumal 88 92 86 84 82 86 86 84 86 85 84 86 126 124 122 118 116 118 124 122 118 118 118 116
74 II newton 76 72 70 76 78 7 74 74 75 72 75 74 130 130 128 128 126 124 126 120 118 116 118 120
75 II saravanan 86 88 86 84 84 86 84 80 80 78 76 76 130 130 126 126 124 124 126 126 122 120 120 126
S.NO GROUP NAME
DIASTOLIC BLOOD PRESSURE - mmHg MEAN ARTERIAL PRESSURE –mmHg
0 10 20 30 40 50 1 1.5 2 2.5 3 6 0 10 20 30 40 50 1 1.5 2 2.5 3 6
minute hours minutes Hours
1 I Srinivasan 70 68 68 64 64 68 68 66 68 66 70 72 83 81 80 77 77 81 81 79 81 80 83 85
2 I Venkatesh 80 80 80 78 78 78 82 82 82 80 82 80 93 93 93 91 91 91 95 95 96 95 94 93
3 I Kumar.s 88 80 80 74 72 70 70 70 70 70 74 72 101 95 93 88 87 86 85 85 85 85 89 87
4 II Ranganathan 84 82 80 80 82 80 82 82 80 80 86 82 98 96 95 95 97 95 97 95 93 93 99 95
5 II Sasikala 70 72 70 72 74 70 70 68 68 68 70 72 83 84 83 84 86 83 83 81 81 81 82 85
6 II Niyamath 80 82 82 86 80 82 80 82 80 76 76 78 93 94 95 96 92 94 93 95 96 92 92 95
7 II Shruthi 70 70 68 68 66 66 68 68 70 66 68 66 82 82 80 80 78 78 80 80 81 79 79 80
8 III Sasikala 70 72 74 70 70 68 68 68 68 72 70 66 83 85 85 83 83 85 81 81 81 84 83 79
9 I Raviraja 80 80 76 76 78 74 70 72 70 72 72 70 93 93 90 90 91 89 87 87 85 87 87 85
10 I Kasi 80 80 82 80 78 78 76 78 80 80 80 76 93 93 95 93 91 91 90 92 94 94 93 90
11 II Moumina 70 70 68 68 72 70 70 72 70 68 66 72 83 83 81 81 85 84 83 87 82 81 79 84
12 I Anavoo 78 78 80 80 78 78 78 80 82 80 78 76 95 95 97 96 94 94 94 95 97 96 94 93
13 I Sajitha 70 70 70 68 68 70 68 70 70 70 68 68 83 83 83 81 81 83 81 82 82 83 81 81
14 III Pradeep 80 82 82 80 80 76 74 76 78 76 72 74 93 95 94 93 93 89 89 89 90 89 87 87
15 III Muchagandhi 72 70 72 74 72 68 66 64 66 62 66 64 91 90 91 92 90 87 85 84 85 82 84 85
16 III Manivanan 80 80 78 78 78 76 76 74 74 74 72 70 93 93 91 91 91 89 89 88 88 87 86 85
17 II Pradeepa 80 80 76 76 78 76 74 72 72 70 70 68 93 93 89 89 90 90 87 85 85 85 85 81
18 III Karthik 86 86 84 84 80 84 84 86 82 82 80 80 99 97 97 98 92 95 95 98 94 94 95 93
19 II Aparna 70 70 70 70 68 68 68 66 66 68 68 70 83 83 83 82 80 80 81 79 80 81 80 84
20 III Devaraj 82 82 80 80 78 78 76 72 72 70 76 78 95 96 93 93 91 91 89 87 87 87 89 91
21 III Rajeshwari 80 80 82 76 76 78 78 76 70 72 74 74 93 94 94 89 89 91 91 89 84 85 86 87
22 I Praveen 80 82 80 86 76 80 78 76 76 76 70 72 93 95 93 97 89 92 91 89 89 89 83 85
23 II Pikkas 74 72 72 72 70 72 70 68 70 70 68 72 88 87 87 85 85 87 85 81 83 84 82 87
24 I Kandasamy 80 84 80 70 70 70 74 70 70 72 76 76 97 101 96 87 87 87 91 87 87 89 91 91
25 II Arumugam 80 80 78 76 70 70 72 74 76 76 72 74 97 97 95 91 87 87 89 91 93 93 89 90
26 III Venkateshan 80 80 80 76 78 76 76 70 76 70 72 70 93 93 95 90 91 89 90 84 88 85 85 86
27 III Anushya 82 82 82 80 78 78 76 76 78 72 70 70 97 97 96 94 91 91 91 91 92 87 87 87
28 III Raj 80 80 80 80 82 78 78 76 76 72 72 78 93 94 93 92 94 91 90 89 89 85 85 91
29 II Vasantha 70 72 70 68 68 70 72 68 66 70 72 68 83 84 82 83 80 83 84 82 82 84 87 85
30 I Tirupathy 70 70 70 64 64 64 62 66 70 72 68 68 83 83 83 78 78 77 77 79 83 85 81 81
31 III Kasi 70 72 72 74 72 70 68 68 68 64 64 66 83 85 87 85 83 83 81 81 81 77 79 79
32 II Guhankumar 80 82 78 74 78 78 80 80 80 76 76 72 93 94 91 88 92 91 93 93 93 89 89 85
33 III Vikkiraj 72 70 76 70 72 72 68 70 68 70 70 68 85 85 87 84 84 83 80 81 81 82 83 83
34 I Jhansirani 80 78 78 78 80 76 82 80 78 80 80 86 93 91 91 91 93 90 95 93 91 93 93 95
35 I Shankar 70 68 68 64 64 68 70 70 70 72 72 72 83 81 81 79 78 81 83 83 83 85 85 85
S NO GROUP NAME
DISTOLIC BLOOD PRESSURE – mm HG MEAN ARTERIAL PRESSURE – mm HG
0 10 20 30 40 50 1 1.5 2 2.5 3 6 0 10 20 30 40 50 1 1.5 2 2.5 3 6
minutes hours minutes Hours
36 II Arumugam 80 78 78 74 72 70 72 72 74 74 74 72 97 94 95 91 91 91 91 91 92 91 91 91
37 I Sandeepkumar 80 80 74 74 82 84 82 82 78 78 72 72 93 93 88 88 95 97 95 95 91 91 87 87
38 III Mariya 82 82 80 80 78 76 78 76 72 70 74 80 95 94 93 94 91 89 91 90 86 85 89 93
39 III Selvakumar 82 82 80 76 80 80 76 76 78 76 78 70 98 98 99 93 93 94 90 91 93 92 93 87
40 III Prabhakaran 78 74 74 72 70 70 74 72 76 72 70 72 93 89 91 87 86 85 87 87 89 87 85 87
41 I Thilakaraj 82 82 86 82 80 80 78 78 74 74 68 70 97 97 99 96 94 94 93 93 89 89 86 88
42 II Lingamoorthy 70 74 72 72 70 72 74 76 72 70 68 68 83 85 84 83 81 83 85 87 85 82 81 81
43 III Boomilingam 82 80 80 78 76 78 74 74 72 76 74 76 95 93 95 91 90 91 87 87 85 89 88 89
44 III Manohar 82 80 82 78 76 76 78 74 78 74 78 74 96 95 95 93 93 91 91 87 91 89 92 89
45 I Tamilselvi 70 70 70 70 68 68 66 68 70 68 66 70 83 83 83 83 81 81 79 81 83 80 79 83
46 II Dineshkumar 70 68 68 68 70 72 72 70 68 66 64 62 83 81 81 81 82 84 84 81 81 79 78 77
47 I Nesiya 70 70 68 72 72 72 70 74 72 70 72 70 83 83 81 83 83 83 83 85 83 81 83 81
48 II Divya 70 70 68 66 68 66 72 70 70 70 72 74 83 83 81 79 81 80 83 82 82 81 83 85
49 III Srinivasan 70 70 72 68 68 70 70 72 68 64 68 68 83 85 84 81 80 82 82 85 81 79 80 80
50 III Ramesh 80 76 76 78 72 72 74 76 76 70 72 72 93 89 89 91 86 86 87 89 89 85 85 85
51 II Girish 76 74 78 74 72 76 70 70 72 72 70 76 87 85 87 85 83 85 82 82 84 84 82 86
52 I Rajesh 70 68 68 66 68 66 66 64 70 66 70 68 83 81 81 79 81 79 79 78 81 78 80 79
53 I Selvi 78 80 80 80 78 76 72 70 70 68 70 70 92 94 95 93 91 89 86 83 82 81 83 83
54 II Prabhakaran 80 80 86 82 78 78 76 70 72 74 70 70 93 94 97 94 91 91 89 83 83 85 83 83
55 III Sanjay 78 78 76 76 70 68 66 70 72 72 70 68 95 95 93 89 87 85 83 87 89 89 88 86
56 III Subramani 80 86 84 80 80 76 78 78 74 70 74 72 95 100 97 94 93 89 91 91 87 84 87 89
57 II Tamilselvi 78 76 74 70 68 70 72 64 68 64 70 70 91 89 87 85 83 83 84 78 81 78 83 83
58 II Nagaraj 80 82 84 84 80 80 78 80 76 72 80 78 97 97 99 98 95 95 93 95 93 89 97 95
59 I Kamaraj 76 76 74 74 72 70 72 74 76 78 78 78 91 91 89 88 86 83 85 85 88 91 91 92
60 I Viswanathan 82 80 84 84 84 80 86 76 74 74 70 72 98 96 99 99 99 96 99 92 91 91 87 88
61 III abdul basher 72 70 72 70 70 70 68 66 68 70 76 76 87 85 87 85 84 83 84 81 83 83 87 89
62 III michael raj 76 76 72 70 72 70 70 68 68 64 68 70 87 87 87 85 85 83 82 80 80 77 79 81
63 I Pandian 76 74 72 70 72 70 74 74 72 74 74 76 90 88 87 85 85 83 87 87 85 87 87 89
64 I Om prakash 90 90 86 80 80 76 78 80 82 84 84 82 103 104 99 93 93 89 91 95 96 98 97 97
65 II Munirathinam 80 80 80 82 86 80 74 76 74 76 80 82 95 95 96 96 98 94 91 91 90 91 95 97
66 II Lakshmi 70 72 74 70 68 68 72 68 68 70 70 72 87 88 90 87 85 85 88 84 85 85 85 87
67 II Revathy 70 70 68 68 66 68 66 66 62 64 64 64 83 83 81 81 79 79 77 79 75 79 77 77
68 III Kuppusamy 74 72 70 70 68 66 68 68 64 66 66 68 89 88 88 87 85 83 84 85 82 83 82 85
69 I Ganesh 80 80 82 84 84 84 82 80 78 76 76 74 93 93 94 97 98 99 96 94 93 91 91 89
70 I Anjali 70 70 70 72 70 68 70 66 64 64 62 70 83 82 82 83 81 81 82 80 77 78 77 83
S. NO GROUP NAME
DISTOLIC BLOOD PRESSURE- mm HG MEAN ARTERIAL BLOOD PRESSURE – mm HG
0 10 20 30 40 50 1 1.5 2 2.5 3 6 0 10 20 30 40 50 1 1.5 2 2.5 3 6
minutes hours minutes Hours
71 I Tamilselvan 78 78 80 80 76 78 76 76 74 76 76 78 91 91 93 93 90 91 90 89 87 89 89 91
72 III michael raj 82 80 80 76 72 78 78 72 74 72 72 74 95 94 93 89 87 91 91 86 87 84 84 86
73 II Perumal 82 80 78 76 74 76 80 80 78 78 76 78 97 95 93 90 88 90 95 94 91 91 90 91
74 II Newton 80 80 78 76 76 74 72 70 70 72 70 76 97 97 95 93 93 91 90 87 86 87 86 91
75 II Saravanan 70 72 72 72 76 78 76 76 72 70 68 64 90 91 90 90 92 93 93 93 89 87 85 85
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